Small molecule conjugates for intracellular delivery of biologically active compounds

ABSTRACT

The invention provides novel compounds and conjugates of these compounds useful for the delivery of biologically active substances. Further novel design criteria for chemically stabilized siRNA particular useful when covalently attached to a delivery polymer to achieve in vivo mRNA knock down are disclosed therein.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a continuation of International Patent Application No. PCT/EP2011/073718, filed Dec. 22, 2011, which claims priority benefit to U.S. Provisional Patent Application No. 61/427,845 filed Dec. 29, 2010, the content of each of which is hereby incorporated herein by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing submitted via EFS-Web and hereby incorporated by reference in its entirety. Said ASCII copy, created on Jun. 11, 2013, is named P5647C1SeqList.txt and is 163,077 bytes in size.

FIELD OF THE INVENTION

The present invention relates to novel small molecule conjugates useful for the delivery of biologically active substances, such as nucleic acids, peptides and proteins. The delivery of nucleic acids and other substantially cell membrane impermeable compounds into a living cell is highly restricted by the complex membrane system of the cell.

One means that has been used to deliver a biologically active substance such as nucleic acids in vivo has been to attach the biologically active substance to either a small targeting molecule or a hydrophobic molecule such as a lipid or sterol. While some delivery and activity has been observed with these conjugates, the biologically active substance dose required with these methods has been prohibitively large, resulting often in undesired toxicity effects in vivo. Provided herein are small molecule compounds that can be conjugated to a biologically active substance and mediate successful delivery of said biologically active substance into a cell. Surprisingly it has been found that significantly decreased doses of the biologically active substance are now sufficient for successful delivery when using the novel compounds provided herein. Thus, the novel compounds provide a powerful tool for the delivery of biologically active substances with considerably limited toxicity in vivo.

BRIEF SUMMARY OF THE INVENTION

In one embodiment, the present invention is directed to the compounds of formula

wherein

-   -   Y is a linker group selected from —(CH₂)₃— or         —C(O)—N—(CH₂—CH₂—O)_(p)—CH₂—CH₂—;     -   R¹ is —(C1-6) alkyl;         -   —(CH₂)-naphthyl; or         -   —(CH₂)_(m)-phenyl, which phenyl is unsubstituted or up to             four times substituted with a substituent independently             selected from —NO₂,             -   —CN,             -   Halogen,             -   —O—(CH₂)-phenyl,             -   —O—(C1-6) alkyl, or             -   —C(O)—NH₂;     -   R² is hydrogen;         -   —(CH₂)_(k)—N—C(Ph)₃, which phenyl rings are unsubstituted or             independently substituted with —O—(C1-4)alkyl;         -   —(CH₂)_(k)—C(O)—NH₂;         -   —(CH₂)_(k)-phenyl;         -   —(C1-6) alkyl, which is unsubstituted or once substituted             with —S—CH₃;     -   R³ is —NH-phenyl, which phenyl group is further substituted with         a substituent independently selected from         -   —(CH₂)—OH; or         -   —(CH₂)—O—C(O)—O-(4-nitro-phenyl);     -   k is 1, 2, 3, 4, 5, 6;     -   m is 1, 2, 3 or 4;     -   n is 0 or 1; and     -   p is an integer from 1 to 20.

In another embodiment, the compounds of formula (I) may have the specific conformation as shown in formula (Ia),

wherein all substituents R¹, R², R³ and Y as well as the variables k, m, n, and p have the meaning given above.

In yet another embodiment, the present invention is directed to compounds of formula (I) or (Ia), wherein Y is —(CH₂)₃—; and all remaining substituent groups have the meaning given above.

In yet another embodiment, the present invention is directed to compounds of formula (I) or (Ia), wherein Y is —C(O)—N—(CH₂—CH₂—O)_(p)—CH₂—CH₂—; and all substituent groups have the meaning given above.

In yet another embodiment, there are provided the compounds of formulae (I) or (Ia), wherein

-   -   Y is —(CH₂)₃—;     -   R² is —(CH₂)_(k)—N—C(Ph)₃, which phenyl rings are unsubstituted         or independently substituted with —O—(C1-4)alkyl; and     -   R³ is —NH-phenyl, which phenyl group is further substituted with         -   —(CH₂)—O—C(O)—O-(4-nitro-phenyl);     -   n is 0; and     -   R¹ and k have the meanings given above.

In yet another embodiment, there are provided the compounds of formulae (I) or (Ia), wherein

-   Y is —C(O)—N—(CH₂—CH₂—O)_(p)—CH₂—CH₂—; -   R² is —(CH₂)_(k)—N—C(Ph)₃, which phenyl rings are unsubstituted or     independently substituted with —O—(C1-4)alkyl; and     -   R³ is —NH-phenyl, which phenyl group is further substituted with         —(CH₂)—O—C(O)—O-(4-nitro-phenyl); -   n is 0; and -   R¹, k and p have the meanings given above.

DETAILED DESCRIPTION OF THE INVENTION

The term “(C1-6) alkyl” as used herein means a linear or branched, saturated hydrocarbon containing from 1 to 6 carbon atoms. Preferred C1-6 alkyl groups include methyl, ethyl, propyl, iso-propyl, butyl, 2-butyl and the like.

The term “halogen” as used herein means fluorine, chlorine, bromine, or iodine with fluorine and chlorine being preferred.

The compounds according to the present invention can be generally obtained using methods known to the person of ordinary skill in the art of organic- or medicinal chemistry. More particularly the compounds of formula (Ia), wherein Y is —(CH₂)₃— and n=0, can be obtained using compound (A) as starting material.

The synthesis of (A) is described inter alia in WO2001/070415.

The compound of formula (A) is further reacted in the presence of Huenig's base and ethyl acetate (AcOET), followed by the addition of dihydrofuran-2,5-dione in THF, to give the compounds of formula (B)

The compounds of formula (B) are further reacted with an amine of formula (C),

to give the compounds of formula (Ia).

The compounds of formula (I) or (Ia) are useful as ligands on biologically active substances, such as nucleic acids, peptides or proteins, to which they are covalently attached. Preferably, the covalent bond is created by the reaction of a suitable functional group, such as i.e. a primary amine group, in the biologically active substance with the activated carbonyl group in the —O—C(O)—O— moiety of R³ as defined herein before. Hence provided herein is a conjugate comprising the compounds of formula (I) or (Ia) and a biologically active substance.

The term “biologically active substance” as used herein refers to an inorganic or organic molecule including a small molecule, peptide (e.g. cell penetrating peptides), protein, carbohydrate (including monosaccharides, oligosaccharides, and polysaccharides), nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, or a small molecule linked to a protein, glycoprotein, steroid, nucleic acid (any form of DNA, including cDNA, or RNA, or a fragment thereof), nucleotide, nucleoside, oligonucleotides (including antisense oligonucleotides, LNA and siRNA), gene, lipid, hormone, or combination thereof, that causes a biological effect when administered in vivo to an animal, including but not limited to birds and mammals, including humans. Preferably, said biologically active substance is a peptide or a nucleic acid. Preferred nucleic acids used herein are siRNAs.

The conjugate comprising the present compounds covalently attached to a biologically active substance shows an improved ability to be taken up by cells compared to said biologically active substance alone. Once the conjugate is delivered into the cell and trafficking to the lysosome, the corresponding biologically active substance is released by enzymatic cleavage. This cleavage preferably takes place when a di-peptide motif, preferably consisting of the sequence α- or β-(phenyl)alanine and lysine as present in the compounds of formula (I) or (Ia) is incorporated in the conjugate (see scheme 1). Most preferably the conjugate contains the di-peptide motif and a spacer such as the p-aminobenzylcarbamate spacer (Bioconjugate Chem. 2002, 13, 855) that spontaneously fragments once the amide bond C-terminal of the di-peptide motif is cleaved as exemplified for siRNAs in scheme 2. Hence the conjugates comprising compounds of formula (I) or (Ia) are also referred to as dipeptide containing cholesterol conjugates. Enzymatic cleavage of the biologically active substance from the dipeptide containing cholesterol conjugates of this invention is catalyzed by innate proteases of the cell. One example of an innate protease capable of cleaving the di-peptide motif present in the compounds of formula (I) or (Ia) is Cathepsin B. Cathepsin B is a known ubiquitous cysteine protease located in the lysosomes of mammalian cells (Bioconjugate Chem. 2002, 13, 855; J. Med. Chem. 2005, 48, 1344; Nat. Biotechnology 2003, 21, 778). Thus, the di-peptide motif described above is also referred to as Cathepsin-cleavable dipeptide-motif.

The present invention therefore also provides a method for delivery of a biologically active substance, into cells wherein said biologically active substance may subsequently be cleaved off the conjugate to unfold a therapeutic activity.

In a further embodiment of the present invention, there is provided a conjugate of the compounds of formula (I) or (Ia) covalently attached to a biologically active compound, preferably siRNA or a peptide moiety. Preferably said peptide moiety is a peptide that exhibits membrane perturbing properties like cell penetrating peptides or amphiphilic peptides.

Conjugates of formula (I) or (Ia) covalently attached to a biologically active substance are designated herein as formula (II) or (IIa), respectively.

Therefore, in a further embodiment, the present invention provides a compound of formula

wherein

-   R^(a) is —(CH₂)_(k)—NH₂; -   R¹ and k have the meanings given for formula (I) above; and     the biologically active substance is a nucleic acid, a protein or a     peptide.

In a more specific embodiment, the present invention provides compounds of formula

wherein

-   R^(a) is —(CH₂)_(k)—NH₂; -   R¹ and k have the meanings given for formula (I) above; and     the biologically active substance is a nucleic acid, a protein or a     peptide.

In a preferred embodiment, the biologically active substance in formula (II) or (IIa) is a nucleic acid, most preferably a siRNA.

In another preferred embodiment, the biologically active substance in formula (II) or (IIa) is a protein or a peptide.

The compounds of formula (II) or (IIa) may have valuable properties in therapy. Therefore, in a further embodiment, there are provided the compounds of formula (II) or (IIa) for use as medicaments.

Another embodiment of the invention is a pharmaceutical composition comprising the conjugates of the compounds of formula (I) or (Ia) covalently attached to a biologically active substance.

In still another embodiment of the invention there is provided a pharmaceutical composition comprising the compounds of formula (IIa) together with pharmaceutically acceptable excipients.

Below embodiments are exemplified for conjugates of the compounds of formula (I) or (Ia) covalently attached to siRNA, thus the compounds of formula (II) or (IIa) wherein the biological active substance is siRNA. It is understood that these embodiments are also applicable for other biologically active substances such as peptides and proteins.

The covalent attachment of the siRNA to the compounds of formula (I) or (Ia) is achieved via reaction of a suitable nucleophilic group, i.e. a primary amine group, in the siRNA with the activated —C(O)— group in R³ of said compounds of formula (I) or (Ia). The activation of that —C(O)— group is obtained by a p-nitrophenoxy carbonate as shown in scheme 2 below.

The p-nitrophenyl activated carbonate may for example be reacted with the siRNA equipped with a hexylamino-linker to generate a carbamate linkage to yield the siRNA conjugate. Once the siRNA is taken up intracellularly and transfected to the lysosome the compounds of formula (II) or (IIa) wherein the biological active substance is siRNA are cleaved by the protease activity releasing the siRNA as also shown in scheme 2. The cholesterol moiety of the conjugate of the compounds of formula (II) or (IIa) modifies the PK properties of siRNA in such a way that systemic administration enables gene silencing in vivo.

In one embodiment the compounds of formula (II) or (IIa) wherein the biological active substance is siRNA is co-administered with a delivery polymer. Delivery polymers provide a means of disrupting cell membranes and mediate endosomal release. In another embodiment, said delivery polymer and the siRNA conjugate of the invention are not covalently attached and synthesized separately and may be supplied in separate containers or a single container. Delivery polymers for oligonucleotides such as siRNA are well known in the art. For example, Rozema et al., in U.S. Patent Publication 20040162260 demonstrated a means to reversibly regulate membrane disruptive activity of a membrane active polyamine. Reversible regulation provided a means to limit activity to the endosomes of target cells, thus limiting toxicity. Their method relied on reaction of amines on the polyamine with 2-propionic-3-methylmaleic anhydride. This modification converted the polycation to a polyanion via conversion of primary amines to carboxyl-containing groups and reversibly inhibited membrane activity of the polyamine. To enable co-delivery of the nucleic acid with the delivery vehicle, the nucleic acid was covalently linked to the delivery polymer. In U.S. provisional patent application 61/307,490 a new generation of delivery polymers is described. Therein, membrane active polyamine comprising an amphipathic terpolymer formed by random polymerization of amine-containing monomers, lower hydrophobic monomers, and higher hydrophobic monomers are provided. This new generation of delivery polymers removed the requirement that polynucleotide and polymer are associated either by covalent linkage or by charge-charge interaction.

Non-limiting examples of delivery polymers used for co-administration with the siRNA conjugates of the invention are membrane active polyamines and poly(vinyl ether) (PBAVE), Dynamic PolyConjugates (DPC; Rozema et al. 2007) and improved DPCs as disclosed in U.S. provisional patent application 61/307,490.

In a further embodiment, a new chemical siRNA modification pattern for functional in vivo delivery is provided. This new chemical siRNA modification pattern is especially useful with delivery vehicles which display a relatively strong endosomal/lysosomal retention.

It was found that siRNA stabilization against degradation by endosomal/lysosomal-localized nucleases such as DNAse II strongly improves target knock down. Such stabilization may directly effect the amount of siRNA released into the cytoplasm where the cellular RNAi machinery is located. Only the siRNA portion available in the cytoplasm will trigger the RNAi effect.

In addition to poor pharmacokinetic characteristics, siRNAs are susceptible to nucleases in the biological environment when administered as such into the circulation without a protecting delivery vehicle. Accordingly, many siRNAs are rapidly degraded either extracellularly in the tissue and blood stream or after intracellular uptake (endosome).

One well known nuclease localized in the endosomal/lysosomal compartment is DNase II. This enzyme is active at a pH below 6-6.5 with maximum activity in the pH-range of 4.5-5, reflecting conditions present in the acidified environment of the endosomal/lysosomal compartment. The following RNA degradation pathways induced by DNase II were identified in vitro and are disclosed in this invention:

A. RNA strands containing at least one 2′-OH nucleotide are rapidly degraded via a cyclic pentavalent phosphorus intermediate, leading to 2′-3′ cyclic phosphates at the 5′-cleavage product. The formation of the pentavalent intermediate can be inhibited by nucleotides lacking a 2′-OH group such as 2′-deoxy, 2′-O-methyl (2′-OMe) or 2′-deoxy-2′-fluoro (2′-F) nucleotides. B. Additionally, RNA is degraded in a 5′-exonucleolytic pathway independent of the 2′-modification on the 5′-terminal nucleotides. This degradation pathway can be inhibited by 5′-terminal non-nucleotide moieties, like e.g. cholesterol, aminoalkyl-linker or a phosphothioate at the first internucleotide linkage. C. A 5′-phosphate also protects and slows down the exonucleolytic cleavage kinetics, but can not fully block this pathway. This is most probably due to the cleavage of the 5′-phosphate by phosphatases or an inherent phosphatase activity of the DNase II enzyme preparation used in the stability assay. D. The best protection was achieved with oligonucleotides lacking any 2′-OH nucleotide within the strand, starting with a 2′-OMe nucleotide at the 5′-end connected by a phosphorothioate (PTO) linkage to the second nucleotide. Other terminal non-2′-OH nucleotides also protect against the 5′-exo degradation, but to a lower extent compared to the 2′-OMe modification.

Hence the inventors of the present invention found that siRNAs can be significantly stabilized when using the following design, wherein an oligonucleotide is provided with an antisense strand with the modification pattern: 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-3′, wherein

w is independently a 5′-phosphate or 5′-phosphothioate or H, Z1 is independently a 2′-modified nuleoside. Z2 is independently a 2′-deoxy nucleoside or 2′-Fluoro-modified nucleoside, Z3 is independently a 2′-modified nucleoside, n_(a) is 8-23 and n_(s) is 8-25.

In one preferred embodiment an oligonucleotide is provided with an antisense strand with the modification pattern: 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-3′, wherein Z1 is a 2′-Fluoro-modified nucleoside or a 2deoxy-nucleoside and all remaining substituents as well as the variables n_(a) and n_(s) have the meaning given above.

In one preferred embodiment an oligonucleotide is provided with an antisense strand with the modification pattern: 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-3′, wherein Z3 is a 2′-O-Methyl modified nucleoside, a 2′-Fluoro-modified nucleoside or a 2deoxy-nucleoside and all remaining substituents as well as the variables n_(a) and n_(s) have the meaning given above.

In one preferred embodiment an oligonucleotide is provided with an antisense strand with the modification pattern: 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-3′, wherein Z1 is a 2′-Fluoro-modified nucleoside or a 2deoxy-nucleoside and Z3 is a 2′-O-Methyl modified nucleoside, a 2′-Fluoro-modified nucleoside or a 2deoxy-nucleoside and all remaining substituents as well as the variables n_(a) and n_(s) have the meaning given above.

The nucleosides in the nucleic acid sequence of the oligonucleotice with the novel modification pattern can either be linked by 5′-3′ phosphodiesters or 5′-3′ phosphorothioates.

As used herein, the “anti-sense” strand is the siRNA strand that is complementary to the target mRNA and that will be binding to the mRNA once the siRNA is unwound.

The sense strand of said siRNA comprising the novel modification pattern is complimentary to the antisense strand.

Said siRNA comprising the novel modification pattern proofed to be particularly advantageous when covalently attached to a delivery polymer as exemplified by Rozema et al. (Dynamic PolyConjugates (DPC; Rozema et al. 2007). Potency and duration of effect can be significantly enhanced employing the siRNA modification strategy outlined in this invention.

In another embodiment, said siRNA comprising the novel modification pattern are especially useful when conjugated to small molecules that alter the pharmacokinetic properties of siRNA such as cholesterol or the compounds of formula (I) and (Ia) provided herein. In one embodiment a conjugate of a small molecule and an oligonucleotide is provided wherein the oligonucleotide has the following modification pattern: the antisense strand with the modification pattern: 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-, wherein the substituents as well as the variables n_(a) and n_(s) have the meaning given above. In one embodiment said small molecule is cholesterol. In another embodiment said small molecule is a compound of formula (I) or (I a), resulting in compounds of formula (II) or (IIa).

Preferably, said siRNAs conjugates are co-administered with a delivery polymer. Suitable delivery polymers are described above.

In one embodiment, said siRNA comprising the novel modification pattern are especially useful when conjugated to a ligand that is known to bind to a specific receptor which internalizes the conjugate into a cell. Particularly, the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes is a well-known receptor enabling the clearance (endocytosis and lysosomal degradation) of desialylated proteins from circulation. It has been shown that the N-Acetyl-D-galactosamine has a high binding affinity for the receptor, especially when presented multivalent and when the galactose residues are properly spaced (J Biol Chem, 2001, 276, 37577). In order to utilize this high capacity receptor for receptor mediated endocytosis of the biologically active substance, the synthetic ligand shown below was prepared to be covalently attached to the siRNAs comprising the novel modification pattern. Since this type of endocytosis leads to lysosomal degradation of the internalized material the siRNA must be prepared in such a way that it is stable in the lysosome, which is now solved by the novel modification pattern outlined above.

The ligand for the ASGPR is attached via an amide bond to the biologically active substance. The amide bond formation can be established with the aid of NHS chemistry. The ligand employed in the conjugation reaction is shown below (formula III). For interaction with the ASGPR the O-acetate groups need to be removed as shown in (formula IV) for an siRNA.

In one embodiment of the invention, a conjugate of a compound of formula IV and an oligonucleotide is provided, wherein the oligonucleotide has the following modification pattern: the antisense strand with the modification pattern 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-, wherein the substituents as well as the variables n_(a) and n_(s) have the meaning given above. Said conjugate is also referred to as GalNAc palmitoyl conjugate. Preferably, said GalNAc palmitoyl conjugate are co-administered with a delivery polymer. Suitable delivery polymers are described above.

It was found that for these modification patterns cleavable linkers proofed to be advantageous compared to stably linked small molecule ligands. Possible cleavable linkersare a di-peptide motifas exemplified in scheme 1 or a cleavable RNA-linker comprising 2′-OH containing nucleotides. The cleavable RNA-linker is especially useful in connection with the siRNAs having the novel modification pattern (fully 2′-modified siRNA) described above.

In principle a nuclease cleavage site can be introduced by 3′- or 5′-overhangs containing at least one 2′-OH nucleotide at either the sense or the antisense strand. The final active siRNA species is generated by intracellular nuclease processing. Also, the use of defined cleavage sites implemented by 2′-OH nucleotides within the base paired region is possible. This can be done using at least one 2′-OH nucleotide complementary to the opposite strand or by introduction of either at least one mismatched 2′-OH nucleotide or a hairpin/bulge containing at least one 2′-OH nucleotide.

In contrast to other cleavable linker chemistries the use of defined cleavage sites by introduction of 2′-OH nucleotides lead to a more versatile conjugation approach. By introducing selective cleavage sites on one or on both strands of the siRNA either at the 3′ and/or the 5′-end or within the duplex structure, multiple conjugation is possible.

Accordingly, in one embodiment, a conjugate of a small molecule and an oligonucleotide is provided wherein

-   -   a) the small molecule comprises a nucleotide linker comprising         1-10 preferably 1-5, most preferably 1-3 2′OH-nucleotides;     -   b) the oligonucleotide has the following modification pattern:         the antisense strand with the modification pattern         5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the         modification pattern 5′-(Z3)n_(s)-, wherein the substituents as         well as the variables n_(a) and n_(s) have the meaning given         above; and     -   c) the oligonucleotide is covalently attached to the nucleotide         linker of the small molecule.

The nucleotide linker is cleaved by intracellular nucleases such as DNAse II after internalization of the conjugate into the endosome, thus releasing the siRNA.

Preferably, said conjugate is co-administered with a delivery polymer. Suitable delivery polymers are described above.

In another embodiment of the invention a compound of formula (V) is provided. This compound comprises a cholesterol moiety, and a nucleotide linker comprising 1-10 preferably 1-5, most preferably 1-3 2′OH-nucleotides. This nucleotide linker is useful for covalently attaching an oligonucleotide such as a siRNA to the compound of formula (V). Preferably, said oligonucleotide has the novel modification pattern outlined above. Hence in another embodiment a conjugate of a compound of formula (V) and an oligonucleotide is provided, wherein the oligonucleotide is covalently attached to the nucleotide linker of the compound of formula (V).

The nucleotide linker is cleaved by intracellular nucleases such as DNAse II after internalization of the conjugate of a compound of formula (V) and an oligonucleotide into the endosome, thus releasing the siRNA.

Preferably, said conjugate of a compound of formula (V) and an oligonucleotide is co-administered with a delivery polymer. Suitable delivery polymers are described above.

In another embodiment, said delivery polymer and the conjugate of a compound of formula (V) and an oligonucleotide of the invention are not covalently attached and synthesized separately and may be supplied in separate containers or a single container.

DEFINITIONS

The term “small molecule” as used herein, refers to organic or inorganic molecules either synthesized or found in nature, generally having a molecular weight less than 10,000 grams per mole, optionally less than 5,000 grams per mole, and optionally less than 2,000 grams per mole.

The term “peptide” as used herein refers to any polymer compound produced by amide bond formation between an .alpha.-carboxyl group of one D- or L-amino acid and an .alpha.-amino group of another D- or L-amino acid. The term “protein” as used herein refers to polypeptides of specific sequence of more than about 50 residues.

The term “di-peptide motif” as used herein refers to any motif comprising an amide bond formed by either the D- or L-alpha or beta amino group of a first amino acid with the alpha-carboxyl group of a second D- or L-amino acid.

As used herein, the term “amino acid” refers to any molecule that contains both amine and carboxyl functional groups. Thus the term “amino acid” refers to both natural, non-natural and synthetic amino acids. Any natural amino acids used in the present invention are referred to herein by their common abbreviations.

The term “ligand” as used herein refers to a moiety that is capable of covalently or otherwise chemically binding a biologically active substance. The term “ligand” in the context of the invention is preferably a compound of formula (I) or (Ia) covalently attached to a biologically active substance.

The term “biologically active substance” as used herein refers to an inorganic or organic molecule including a small molecule, peptide (e.g. cell penetrating peptides), protein, carbohydrate (including monosaccharides, oligosaccharides, and polysaccharides), nucleoprotein, mucoprotein, lipoprotein, synthetic polypeptide or protein, or a small molecule linked to a protein, glycoprotein, steroid, nucleic acid (any form of DNA, including cDNA, or RNA, or a fragment thereof), nucleotide, nucleoside, oligonucleotides (including antisense oligonucleotides, LNA and siRNA), gene, lipid, hormone, or combination thereof, that causes a biological effect when administered in vivo to an animal, including but not limited to birds and mammals, including humans. Preferably, said biologically active substance is a peptide or a nucleic acid. Preferred nucleic acids used herein are siRNAs.

The term “nucleic acid” as used herein means an oligomer or polymer composed of nucleotides, e.g., deoxyribonucleotides or ribonucleotides, or compounds produced synthetically (e.g., PNA as described in U.S. Pat. No. 5,948,902 and the references cited therein) which can hybridize with naturally occurring nucleic acids in a sequence specific manner analogous to that of two naturally occurring nucleic acids, e.g., can participate in Watson-Crick base pairing interactions. Non-naturally occurring nucleic acids are oligomers or polymers which contain nucleobase sequences which do not occur in nature, or species which contain functional equivalents of naturally occurring nucleobases, sugars, or inter-sugar linkages, like peptide nucleic acids (PNA), threose nucleic acids (TNA), locked nucleic acids (LNA), or glycerol nucleic acids (GNA). This term includes oligomers that contain the naturally occurring nucleic acid nucleobases adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U), as well as oligomers that contain base analogs or modified nucleobases. Nucleic acids can derive from a variety of natural sources such as viral, bacterial and eukaryotic DNAs and RNAs. Other nucleic acids can be derived from synthetic sources, and include any of the multiple oligonucleotides that are being manufactured for use as research reagents, diagnostic agents or potential and definite therapeutic agents. The term includes oligomers comprising of a single strand nucleic acid or a double strand nucleic acid.

The term “2′-modified” as used herein refers to a β-D-ribonucleoside or β-D-ribonucleotide comprising of naturally occurring nucleobases having the 2′-OH group replaced by H, F, O—CH3 or other substituents known in the art.

The term “2′—OH-nucleotide” as used herein refers to β-D-ribonucleotide comprising of naturally occurring nucleobases having a 2′-OH group.

The term “5′-phosphate” as used herein refers to the formula —O—P(═O)(OH)OH. In another aspect the phosphate is modified that one of the O or OH groups is replaced by S and termed herein as “5′-phosphothioate”

The term “phosphorothioate” as used herein refers to a internucleotide linkage in which one of the non-bridging oxygens is replaced by sulfur.

The term “delivery polymer” as used herein refers to polymers suitable for functional delivery of a biologically active substance. In the context of the present invention the delivery polymer is either covalently attached to or coadministered with the biologically substance conjugated to the compounds described herein and mediates endosomal escape after internalization into the cell and uptake into the endosome. The term “polymer” in this context means any compound that is made up of two or more monomeric units covalently bonded to each other, where the monomeric units may be the same or different, such that the polymer may be a homopolymer or a heteropolymer. Representative polymers include peptides, polysaccharides, nucleic acids and the like, where the polymers may be naturally occurring or synthetic. Non-limiting examples of delivery polymers are for example reviewed in INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND DEVELOPMENT, October—2010/Volume—2/Issue—8/Article No—2. Non-limiting examples of delivery polymers useful for delivery of nucleic acids are disclosed in EP applications 10165502.5 and 10191030.5, PCT publication WO 2008/0022309 and U.S. provisional application 61/307,490 and references cited herein; which are all included by reference.

As used herein, “pharmaceutical composition” includes the conjugates of the invention, a pharmaceutical carrier or diluent and any other media or agent necessary for formulation.

As used herein, “pharmaceutical carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g. by injection or infusion).

A conjugate of the present invention can be administered by a variety of methods known in the art. As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. To administer a conjugate of the invention by certain routes of administration, it may be necessary to coat the conjugate with, or co-administer the conjugate with, a material to prevent its inactivation. For example, the conjugate may be administered to a subject in an appropriate carrier or a diluent. Pharmaceutically acceptable diluents include saline and aqueous buffer solutions. Pharmaceutical carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is known in the art.

The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.

These carriers may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of presence of microorganisms may be ensured both by sterilization procedures, supra, and by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

Regardless of the route of administration selected, the conjugates of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

The pharmaceutical composition must be sterile and fluid to the extent that the composition is deliverable by syringe. In addition to water, the carrier preferably is an isotonic buffered saline solution.

Proper fluidity can be maintained, for example, by use of coating such as lecithin, by maintenance of required particle size in the case of dispersion and by use of surfactants. In many cases, it is preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol or sorbitol, and sodium chloride in the composition.

SHORT DESCRIPTION OF THE FIGURES

FIG. 1 shows Co-Administration of siRNA-conjugates comprising the compounds of formula (I) or (Ia) and a delivery polymer in vivo.

FIG. 2 shows Co-Administration of siRNA-conjugates comprising the compounds of formula (I) or (Ia) and a delivery polymer in vivo.

FIG. 3 shows Co-Administration of siRNA-conjugates comprising the compounds of formula (I) or (Ia) and a delivery polymer in vivo.

FIG. 4 shows Co-Administration of siRNA-conjugates comprising the compounds of formula (I) or (Ia) and a delivery polymer in vivo.

FIG. 5 a shows antisense strand mediated gene silencing with fully 2′-modified siRNAs. COS7 cells were cotransfected with EGFP-directed siRNAs at 3 nM and psiCHECK2-AT. The knockdown activity of the siRNAs was assessed by measuring renilla versus firefly luciferase activity from the reporter construct. siRNAs were sorted by knockdown activity of unmodified (2-19-2) reference siRNAs.

FIG. 5 b shows sense strand mediated gene silencing with fully 2′-modified siRNAs. COS7 cells were cotransfected with EGFP-directed siRNAs at 3 nM and psiCHECK2-ST. The knockdown activity of the siRNAs was assessed by measuring luciferase expression from the reporter construct. siRNAs were sorted by knockdown activity of unmodified (2-19-2) reference siRNAs.

FIG. 6 a shows reduction of serum FVII activity in non-human primates upon intravenous injection of various 2′-modified siRNAs covalently attached to a delivery polymer.

FIG. 6 b shows the development of the prothrombin time in non-human primates upon treatment with 2′-modified siRNAs covalently conjugated to a delivery polymer.

The invention will be more fully understood by reference to the following examples. They should not, however, be construed as limiting the scope of the invention.

EXAMPLES Example 1 Step 1: 3-[(3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy]-propylamine

The title amine was prepared from its nitrile precursor according to a literature protocol [Lollo et al, WO2001/070415].

Step 2: N-{3-[(3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy]-propyl}-succinamic acid

In a 2 μL round-bottomed flask, 3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propan-1-amine (21.15 g, 47.7 mmol, Eq: 1.00) and Huenig's base (12.3 g, 16.6 ml, 95.3 mmol, Eq: 2.00) were combined with AcOEt (845 ml) to give a colorless solution. Dihydrofuran-2,5-dione (4.77 g, 47.7 mmol, Eq: 1.00) in THF (42 ml) was added and the reaction mixture was stirred at ambient temperature over night=> white suspension. All volatiles were removed i. v., the residue dissolved in CH₂Cl₂, the organic layer washed with NH4Cl and brine, dried over Na2SO4, and evaporated to dryness. The crude product was dissolved in CH3CN/H2O and lyophilized to yield 29.8 g of the title compound as fluffy powder. MS (ISP): (M−H) 542.5.

Step 3: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-6-((4-methoxyphenyl)diphenylmethylamino)-1-oxohexan-2-ylamino)-3-(4-nitrophenyl)-1-oxopropan-2-yl)succinamide

In a 10 mL round-bottomed flask, the above prepared 4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanoic acid (106 mg, 184 μmol, Eq: 1.00), (S)-2-((S)-2-amino-3-(4-nitrophenyl)propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenylmethylamino)hexanamide (132 mg, 184 μmol, Eq: 1.00), HOAt (25.0 mg, 184 μmol, Eq: 1.00) and EDC hydrochloride (35.3 mg, 184 μmol, Eq: 1.00) were mixed together in CH₂Cl₂ (1.8 ml) to give a yellow solution. Huenig's Base (47.5 mg, 64.2 μl, 368 μmol, Eq: 2.00) was added and the reaction stirred at ambient temperature over night. TLC indicated the consumption of starting material. All volatiles were removed i. V. and the crude product purified by flash chromatography SiO2/7% MeOH/0.1% NEt3 in CH₂Cl₂ to produce 128 mg of the title compound as light yellow solid. MS: expected mass: 1240.7552, found mass: 1240. 7518.

Step 4:

In a 10 mL round-bottomed flask, the above prepared N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-6-((4-methoxyphenyl)diphenylmethylamino)-1-oxohexan-2-ylamino)-3-(4-nitrophenyl)-1-oxopropan-2-yl)succinamide (126 mg, 101 μmol, Eq: 1.00) and Huenig's base (39.3 mg, 53.2 μl, 304 μmol, Eq: 3.00) were combined with CH₂Cl₂ (1.4 ml) and DMF (1.0 ml) to give a yellow suspension; bis(4-nitrophenyl) carbonate (46.3 mg, 152 μmol, Eq: 1.50) was added and the reaction allowed to proceed over night. The mixture was poured onto crashed ice, extracted 2× with AcOEt, washed with H2O, dried over Na2SO4, and evaporated to dryness. After trituration with ˜10 ml of diethyl ether, 99 mg of the title product was obtained as an off-white solid. MS: expected mass: 1405.7614, found mass: 1405.7518.

The necessary dipeptide building block for step 3 was prepared as follows:

Step a: (S)-2-[(S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-(4-nitro-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid

In a 25 mL round-bottomed flask, (S)-2-amino-6-((4-methoxyphenyl)diphenylmethyl-amino)hexanoic acid (Bioconjugate Chem. 2002, 13, 855-869, 968 mg, 2.31 mmol, Eq: 1.00) was dissolved in CH₂Cl₂ (20 ml) to give a light yellow solution. Huenig's base (897 mg, 1.21 ml, 6.94 mmol, Eq: 3.00) and trimethylchlorosilane (528 mg, 621 μl, 4.86 mmol, Eq: 2.10) were added and the reaction mixture was stirred for 15 min.

In a second 50 mL round-bottomed flask, (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-nitrophenyl)propanoic acid (1 g, 2.31 mmol, Eq: 1.00) was dissolved in DMF (20 ml) to give a colorless solution. Huenig's base (359 mg, 485 μl, 2.78 mmol, Eq: 1.20) and TPTU [125700-71-2](687 mg, 2.31 mmol, Eq: 1.00) were added and the reaction mixture was stirred for 20′. The solution from the first flask containing the corresponding silyl ester monosilylamine was added and the reaction was stirred for another 3 hours. The mixture was poured onto crashed ice/NH₄Cl, extracted 2× with AcOEt, washed with H2O and brine, dried over Na2SO4, and evaporated to dryness. Flash chromatography SiO2/10% MeOH/0.1% NEt3 in CH₂Cl₂ afforded 1.38 g of the title compound as brownish foam. MS (ISP): (M+H) 833.5, (M+Na) 855.4.

Step b: [(S)-1-((S)-1-(4-Hydroxymethyl-phenylcarbamoyl)-5-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-pentylcarbamoyl)-2-(4-nitro-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester

In a 250 mL pear-shaped flask, the above synthesized (S)-2-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-nitrophenyl)propanamido)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanoic acid (1.38 g, 1.66 mmol, Eq: 1.00), (4-aminophenyl)methanol (204 mg, 1.66 mmol, Eq: 1.00), HOAt (226 mg, 1.66 mmol, Eq: 1.00) and EDC hydrochloride (318 mg, 1.66 mmol, Eq: 1.00) were dissolved in CH₂Cl₂ (16.6 ml) to give a yellow solution. Huenig's base (428 mg, 579 μl, 3.31 mmol, Eq: 2.00) was added and the reaction allowed to proceed over night. The mixture was poured onto crashed ice/NH₄Cl (pH˜7), extracted 2× with AcOEt, washed with H2O, dried over Na2SO4, and evaporated to dryness. The crude product was triturated with diethyl ether (1×50 mL); the resultant solid was filtered off and dryed to yield 1.214 g of the title compound as light-brown solid. MS (ISP): (M+H) 938.7.

Step c: (S)-2-[(S)-2-Amino-3-(4-nitro-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide

In a 50 mL round-bottomed flask, the above prepared [(S)-1-((S)-1-(4-hydroxymethyl-phenylcarbamoyl)-5-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-pentylcarbamoyl)-2-(4-nitro-phenyl)-ethyl]-carbamic acid 9H-fluoren-9-ylmethyl ester (1.214 g, 1.29 mmol, Eq: 1.001) was combined with THF (19 ml) to give a brown solution. At 0°, diethylamine (1.77 g, 2.49 ml, 24.2 mmol, Eq: 18.70) was added. The reaction was stirred at ambient temperature for 3 h when MS indicated the disappearance of the starting material. All volatiles were evaporated i. V.; ensuing flash chromatography SiO2/0.1% NEt3 in CH2Cl2=>10% MeOH/0.1% NEt3 in CH₂Cl₂, followed by a second flash chromatography SiO2/5% MeOH/0.1% NEt3 in CH₂Cl₂ afforded 502 mg of the title compound as light brown foam. MS: expected mass: 715.337, found mass: 715.3362.

Example 2 O-Benzyl-N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-tyrosyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-[(S)-2-amino-3-(4-benzyloxy-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-(benzyloxy)phenyl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1466.8182, found mass: 1466.8136.

Example 3 N-[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-4-cyano-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-[(S)-2-amino-3-(4-cyano-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-cyanophenyl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1385.7716, found mass: 1385.7696.

Example 4

3,4-Dichloro-N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-[(S)-2-amino-3-(3,4-dichloro-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(3,4-dichlorophenyl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1428.6984, found mass: 1428.695.

Example 5 4-Chloro-N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-((S)-2-amino-3-(4-chlorophenyl)propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)-carbonylamino)-3-(4-chlorophenyl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1394.7373,

found mass: 1394.7342.

Example 6 4-{[(2S)-2-{[(2S)-2-[(4-{[3-({(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl}oxy)propyl]amino}-4-oxobutanoyl)amino]-3-(naphthalen-1-yl)propanoyl]amino}-6-{[(4-methoxyphenyl)(diphenyl)methyl]amino}hexanoyl]amino}benzyl 4-nitrophenyl carbonate (non-preferred name)

Was prepared in analogy to Example 1, but using in step 3 (S)-2-((S)-2-amino-3-naphthalen-1-yl-propionylamino)-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(naphthalen-1-yl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1410.792, found mass: 1410.7918.

Example 7 N-[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-4-fluoro-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-[(S)-2-amino-3-(4-fluoro-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)-hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-fluorophenyl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1378.7669, found mass: 1378.7609.

Example 8 N-[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-2-fluoro-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-[(S)-2-Amino-3-(2-fluoro-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)-hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(2-fluorophenyl)propanoic acid as described above in steps a]-c].

MS: expected mass: 1378.7669, found mass: 1378.7689.

Example 9 N-[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-3-fluoro-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-[(S)-2-amino-3-(3-fluoro-phenyl)-propionylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)-hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(3-fluorophenyl)propanoic acid as described above in steps a]-c]. MS: expected mass: 1378.7669, found mass: 1378.7659.

Example 10 Step 1: N1-(3-((3S,8,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-(4-fluorophenyl)-4-((S)-1-(4-(hydroxymethyl)phenylamino)-6-((4-methoxyphenyl)diphenylmethylamino)-1-oxohexan-2-ylamino)-4-oxobutan-2-yl)succinamide

In a 10 mL round-bottomed flask, the above prepared 4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanoic acid (109 mg, 188 μmol, Eq: 1.00), (S)-2-[(S)-3-amino-4-(4-fluoro-phenyl)-butyrylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide (132 mg, 188 μmol, Eq: 1.00), HOAt (25.6 mg, 188 μmol, Eq: 1.00) and EDC hydrochloride (36.1 mg, 188 μmol, Eq: 1.00) were mixed together in CH₂Cl₂ (2 ml) to give a yellow solution. Huenig's Base (48.7 mg, 64.1 μl, 377 μmol, Eq: 2.00) was added and the reaction stirred at ambient temperature over night. TLC indicated the consumption of starting material. All volatiles were removed i. V. and the crude product purified by flash chromatography SiO2/5% MeOH/0.1% NEt3 in CH₂Cl₂ to yield 197 mg of the title compound as off-white solid. MS: expected mass: 1227.7763, found mass: 1227.7714.

Step 2: 4-((S)-2-((S)-3-(4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanamido)-4-(4-fluorophenyl)butanamido)-6-((4-methoxyphenyl)diphenylmethylamino)hexanamido)-benzyl 4-nitrophenyl carbonate

In a 10 mL round-bottomed flask, the above prepared N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-(4-fluorophenyl)-4-((S)-1-(4-(hydroxymethyl)phenylamino)-6-((4-methoxyphenyl)diphenylmethylamino)-1-oxohexan-2-ylamino)-4-oxobutan-2-yl)succinamide (196 mg, 160 μmol, Eq: 1.00) and Huenig's base (61.9 mg, 81.4 μl, 479 μmol, Eq: 3.00) were combined with CH₂Cl₂ (1.6 ml) and DMF (0.8 ml) to give a yellow suspension; bis(4-nitrophenyl) carbonate (72.8 mg, 239 μmol, Eq: 1.50) was added and the reaction allowed to proceed at ambient temperature over night. The mixture was poured onto crashed ice/NH4Cl (pH˜6), extracted 2× with AcOEt, washed with H2O and brine, dried over Na2SO4, and evaporated to dryness. After trituration with AcOEt/heptane one obtained 123 mg of the title compound as light yellow solid. MS: expected mass: 1392.7825, found mass: 1392.7819.

The necessary dipeptidic building block for step 1 was prepared as follows:

Step a: (S)-2-[(S)-3-(9H-Fluoren-9-ylmethoxycarbonylamino)-4-(4-fluoro-phenyl)-butyrylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid

In a 25 mL round-bottomed flask, (S)-2-amino-6-((4-methoxyphenyl)diphenylmethyl-amino)hexanoic acid (Bioconjugate Chem. 2002, 13, 855-869, 1040 mg, 2.48 mmol, Eq: 1.00) was dissolved in CH₂Cl₂ (12.5 ml) to give a pale yellow solution. Huenig's base (961 mg, 1.27 ml, 7.44 mmol, Eq: 3.00) and trimethylchlorosilane (566 mg, 621 μl, 5.21 mmol, Eq: 2.10) were added and the reaction mixture was stirred at ambient temperature for 20 min.

In a second 50 mL round-bottomed flask, (S)-3-(((9H-fluoren-9-yl)methoxy)carbonyl-amino)-4-(4-fluorophenyl)butanoic acid (1040 mg, 2.48 mmol, Eq: 1.00) was dissolved in DMF (12.5 ml) to give a colorless solution. Huenig's base (385 mg, 506 μl, 2.98 mmol, Eq: 1.20) and TPTU [125700-71-2](737 mg, 2.48 mmol, Eq: 1.00) were added and the reaction mixture was stirred for 15 min. The solution from the first flask containing the corresponding silyl ester monosilylamine was added and the reaction was stirred for another 3 hours at ambient temperature. The mixture was poured onto crashed ice/NH₄Cl, extracted 2× with AcOEt, washed with H2O and brine, dried over Na2SO4, and evaporated to dryness. Flash chromatography SiO2/5% MeOH/0.1% NEt3 in CH₂Cl₂ afforded 2.10 g of the title compound as yellow foam. MS (ISP): (M+H) 820.6.

Step b: {(S)-2-(4-Fluoro-phenyl)-1-[((S)-1-(4-hydroxymethyl-phenylcarbamoyl)-5-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-pentylcarbamoyl)-methyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester

In a 250 mL pear-shaped flask, the above synthesized {(S)-2-(4-fluoro-phenyl)-1-[((S)-1-(4-hydroxymethyl-phenylcarbamoyl)-5-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-pentylcarbamoyl)-methyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester (2.10 g, 2.56 mmol, Eq: 1.00), (4-aminophenyl)methanol (315 mg, 2.55 mmol, Eq: 1.00), HOAt (349 mg, 2.56 mmol, Eq: 1.00) and EDC hydrochloride (491 mg, 2.56 mmol, Eq: 1.00) were dissolved in CH₂Cl₂ (12.5 ml). Huenig's base (662 mg, 871 μl, 5.21 mmol, Eq: 2.00) was added and the reaction allowed to proceed over night. The mixture was poured onto crashed ice/NH₄Cl (pH˜7), extracted 2× with AcOEt, washed with H2O and brine, dried over Na2SO4, and evaporated to dryness. The crude product was triturated with diethyl ether (1×50 ml); the resultant solid was filtered off and dryed to yield 0.796 g of the title compound as light-brown solid. MS (ISP): (M+H) 925.6.

Step c: (S)-2-[(S)-3-Amino-4-(4-fluoro-phenyl)-butyrylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide

In a 50 mL round-bottomed flask, the above prepared {(S)-2-(4-fluoro-phenyl)-1-[((S)-1-(4-hydroxymethyl-phenylcarbamoyl)-5-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-pentylcarbamoyl)-methyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester (793 mg, 857 mol, Eq: 1.001) was combined with THF (12 ml) to give a brownish solution. At 0°, diethylamine (1.13 g, 1.59 ml, 15.4 mmol, Eq: 18) was added. The reaction was stirred at ambient temperature over night. The mixture was poured onto crashed ice/NH₄Cl (pH˜7), extracted 2× with AcOEt, washed with H2O and brine, dried over Na2SO4, and evaporated to dryness. Flash chromatography SiO2/10% MeOH/0.1% NEt3 in CH₂Cl₂ yielded 500 mg of the title compound as off-white solid. MS: expected mass: 702.3581, found mass: 702.3578.

Example 11 4-((S)-2-((S)-3-(4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanamido)-4-phenylbutanamido)-6-((4-methoxyphenyl)diphenylmethylamino)hexanamido)benzyl 4-nitrophenyl carbonate

Was prepared in analogy to Example 10, but using in step 1 (S)-2-((S)-3-amino-4-phenylbutanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide instead of (S)-2-[(S)-3-amino-4-(4-fluoro-phenyl)-butyrylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide as coupling partner. The former was prepared from (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-phenylbutanoic acid as described above in steps a]-c]. MS: expected mass: 1374.792, found mass: 1374.7877.

Example 12 4-({N˜2˜-[(3S)-4-(4-chlorophenyl)-3-{[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]amino}butanoyl]-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-L-lysyl}amino)benzyl 4-nitrophenyl carbonate

Was prepared in analogy to example 10, but using in step 1 (S)-2-((S)-3-amino-4-(4-chlorophenyl)butanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)-diphenylmethylamino)hexanamide instead of (S)-2-[(S)-3-amino-4-(4-fluoro-phenyl)-butyrylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide as coupling partner. The former was prepared from (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(4-chlorophenyl)-butanoic acid as described above in steps a]-c]. MS (ISP): (M+H) 1409.9.

Example 13 N-[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-O-methyl-L-tyrosyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Was prepared in analogy to Example 1, but using in step 3 (S)-2-((S)-2-amino-3-(4-methoxyphenyl)propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)-diphenylmethylamino)hexanamide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. The former was prepared from (S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4-methoxyphenyl)propanoic acid as described above in steps a]-c] of example 1. MS (ISP): (M+H) 1391.9.

Example 14 N-[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-D-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-D-lysinamide

Was prepared in analogy to example 1, but using in step 3 (R)-2-((R)-2-amino-3-phenyl-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenylmethyl)amino)-hexanamide instead of (S)-2-((S)-2-amino-3-(4-nitrophenyl)-propanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide as coupling partner. This building block was synthesized from (R)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-6-aminohexanoic acid and (R)-2-amino-6-((4-methoxyphenyl)-diphenylmethylamino)hexanoic acid (see Bioconjugate Chem. 2002, 13, 885-869) as described above in steps a]-c]. MS: expected mass: 1360.7763, found mass: 1360.7774.

Example 15 4-({N˜2˜-[(3S)-3-{[4-({3-[(3Beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]amino}-4-(4-cyanophenyl)butanoyl]-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-L-lysyl}amino)benzyl 4-nitrophenyl carbonate

Was prepared in analogy to example 10, but using in step 1 (S)-2-((S)-3-amino-4-(4-cyanophenyl)butanamido)-N-(4-(hydroxymethyl)phenyl)-6-((4-methoxyphenyl)diphenyl-methylamino)hexanamide instead of (S)-2-[(S)-3-amino-4-(4-fluoro-phenyl)-butyrylamino]-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide as coupling partner. The former was prepared from (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(4-cyanophenyl)butanoic acid as described above in steps a]-c]. MS: expected mass: 1399.7872, found mass: 1399.7857.

Example 16 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

Step 1: (S)-2-((S)-2-Amino-3-phenyl-propionylamino)-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide

The building block (S)-2-((S)-2-amino-3-phenyl-propionylamino)-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide was prepared in analogy to the procedure described in Bioconjugate Chem., Vol. 13, No. 4, 2002, 855-869 MS (ISP): (M+H) 671.5

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-6-((4-methoxyphenyl)diphenylmethylamino)-1-oxohexan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)succinamide

TPTU [125700-71-2](233 mg, 784 μmol, Eq: 1.00) was added to a solution of N-{3-[(3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy]-propyl}-succinamic acid (see example 1, step 2) (426 mg, 0.784 mmol, Eq: 1.00) and Huenig's base (304 mg, 411 μl, 2.35 mmol, Eq: 3) in DMF (10 ml). After 3 minutes (S)-2-((S)-2-amino-3-phenyl-propionylamino)-6-{[(4-methoxy-phenyl)-diphenyl-methyl]-amino}-hexanoic acid (4-hydroxymethyl-phenyl)-amide (step 1) was added TLC at t=1 h showed the reaction was complete. The solvent was removed under reduced pressure. The remaining residue was taken up in ethyl acetate and extracted with NaHCO₃ half sat. solution (1×), potassium hydrogen phthalate solution 0.05M (2×), water (1×) and brine (1×). The organic extract was dried over MgSO₄ and concentrated under reduced pressure. The crude material was purified by flash chromatography to obtain the titled product (682 mg, 513, μmol) as a light brown solid. MS (ISP): (M+H) 1196.8

Step 3: Hünig's base (465 mg, 629 μl, 3.6 mmol, Eq: 6) was added to a solution of the previous alcohol (718 mg, 600 μmol, Eq: 1.00) and bis(4-nitrophenyl) carbonate (548 mg, 1.8 mmol, Eq: 3) in THF (20 ml). The yellow solution was stirred overnight at room temperature. The solvent was removed under reduced pressure. The remaining residue was triturated with diethyl ether. The solid was collected by filtration, washed with ether and dried under reduced pressure to obtain the title compound (800 mg, 529 μmol) as a light brown solid. MS (ISP): (M+H) 1361.9

Example 17 Step 1 (S)-2-[(S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-phenyl-propionylamino]-hexanoic acid

Commercially available L-Fmoc-Phe-OSu (0.969 g, 2.00 mmol, Eq: 1.00) was suspended in a 1:1 v/v mixture of 1,2-dimethoxyethane and water (17 ml) and treated at 0° C. with L-norleucine (0.275 g, 2.10 mmoll, Eq: 1.05) and NaHCO₃ (0.185 g, 2.20 mmol, Eq: 1.10). The cooling bath was removed and the reaction allowed to proceed at ambient temperature for 14 h. The mixture was poured onto crashed ice/citric acid (pH˜3), extracted 2× with ethyl acetate, washed with H2O and brine, dried over Na2SO4, and evaporated to dryness. Flash chromatography SiO2/AcOEt yielded 0.870 mg of the title compound as white solid. MS (ISP): (M+H) 501.2.

Step 2: {(S)-1-[(S)-1-(4-Hydroxymethyl-phenylcarbamoyl)-pentylcarbamoyl]-2-phenyl-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester

In a pear-shaped flask, the above synthesized (S)-2-[(S)-2-(9H-fluoren-9-ylmethoxy-carbonylamino)-3-phenyl-propionylamino]-hexanoic acid (10.72 g, 21 mmol, Eq: 1.00), (4-aminophenyl)methanol (2.717 g, 22 mmol, Eq: 1.03), and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) (7.994 g, 32 mmol, Eq: 1.50) were dissolved in CH₂Cl₂ (320 ml) and stirred overnight under a balloon of Ar. The mixture was poured onto crashed ice/NH₄Cl, extracted 2× with AcOEt, washed with H2O, dried over Na2SO4, and the volume reduced to ˜300 ml. The precipitate was filtered off and dryed to give 5.25 g of the title compound as light-brown solid. MS (ISP): (M+H) 606.3.

Step 3: (S)-2-((S)-2-Amino-3-phenyl-propionylamino)-hexanoic acid (4-hydroxymethyl-phenyl)-amide

In a round-bottomed flask, the above prepared {(S)-1-[(S)-1-(4-hydroxymethyl-phenylcarbamoyl)-pentylcarbamoyl]-2-phenyl-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester (4.738 g, 7.822 mmol, Eq: 1.0) was dissolved in CH₂Cl₂ (28 ml). At 0°, diethylamine (28 ml, 19.80 g, 271 mmol, Eq: 35) was added and the reaction mixture stirred at ambient temperature overnight. All volatiles were evaporated i. V.; ensuing flash chromatography SiO2/CH2Cl2/10% MeOH, followed by crystallization from AcOEt, yielded 2.116 g of the title compound as light brown crystals. MS (ISP): (M+H) 384.2.

Step 4: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-1-oxohexan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)succinamide

was prepared therewith in analogy to example 16 step 2. MS (ISP): (M+H) 909.7 (M+Na) 931.8.

Step 5: N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-norleucinamide

was prepared therewith in analogy to example 16 step 3. MS expected mass: 1073.6453, found mass 1073.642

Example 18 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-alanyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]glycinamide

Step 1: Addition of FMOC-4-Aminobenzylalcohol to the 2-chlorotrityl resin

2-Chlorotrityl chloride resin (Novabiochem 01-64-0114, 100-200 mesh), 1% DVB (18 g, 21.6 mmol, Eq: 1.00) was swollen in DCM/DMF=1/1 (300 mL) for ten minutes. The resin was drained and a solution of FMOC-4-aminobenzyl alcohol (14.9 g, 43.2 mmol, Eq: 2) and pyridine (6.83 g, 6.99 ml, 86.4 mmol, Eq: 4) in DCM/DMF=1/1 (300 mL) was added. The mixture was shaken overnight. The resin was drained and capped with a solution of 10% Hünig's Base in methanol (300 mL). The resin was washed with DMF and DCM and dried over night with HV to obtain 21.7 g resin. Determination of the load resulted in 0.41 mmoL/g. Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-(2-(4-(hydroxymethyl)phenylamino)-2-oxoethylamino)-1-oxopropan-2-yl)succinamide

The resin from step 1 (1 g, 410 μmol, Eq: 1.00) was prewashed with DMF (2×) and treated with piperidine/DMF=1/4 (10 mL) for 5 and 10 minutes. The resin was washed alternately with DMF and IPA (3×10 mL). A solution of Fmoc-Gly-OH (488 mg, 1.64 mmol, Eq: 4), TPTU (487 mg, 1.64 mmol, Eq: 4) and Huenig's base (636 mg, 859 μl, 4.92 mmol, Eq: 12) in DMF (10 mL) was stirred for 5 minutes and then shaken with the resin for one hour. The resin was washed alternately with DMF and isopropyl alcohol (3×).

The following Fmoc cleavages and subsequent couplings of Fmoc-Ala-OH (511 mg, 1.64 mmol, Eq: 4) and N-{3-[(3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy]-propyl}-succinamic acid (example 1, step 2) (892 mg, 1.64 mmol, Eq: 4) were performed accordingly. The dried peptide resin was stirred for about 2×30 min in TFA 1%/DCM (2×20 mL). The reaction mixture was filtered and the resin was washed with DCM. The filtrates were pooled and the solvents evaporated under vacuum. The crude material was triturated with diethyl ether (2×). After purification by flash chromatography, the product (84 mg, 97.3 μmol) was obtained as a white solid. MS expected mass: 776.5452, found mass 776.5455

Step 3: The above prepared alcohol N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-(2-(4-(hydroxymethyl)phenylamino)-2-oxoethylamino)-1-oxopropan-2-yl)succinamide [RO5545270](70 mg, 90.1 μmol, Eq: 1.00) and bis(4-nitrophenyl) carbonate (137 mg, 450 μmol, Eq: 5) under Argon at room temperature were dissolved in DMF (4 ml) and treated with Huenig's base (34.9 mg, 47.2 μl, 270 μmol, Eq: 3). and the mixture was allowed to react overnight. The solvent was removed in vacuo. The resulting solid was triturated with diethylether. The solid was collected by filtration and washed with diethyl ether. The product was dried in vacuo to obtain the title compound (84 mg, 80.2 μmol) as a light brown solid. MS expected mass: 941.5514, found mass 941.5518

Example 19 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-leucyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-methioninamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

was prepared in analogy to example 18, step 1

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-4-(methylthio)-1-oxobutan-2-ylamino)-4-methyl-1-oxopentan-2-yl)succinamide

was prepared in analogy to example 18, step 2, using Fmoc-Met-OH (609 mg, 1.64 mmol, Eq: 4) and Fmoc-Leu-OH (580 mg, 1.64 mmol, Eq: 4) as amino acids. The product (208 mg, 210 μmol) was obtained as a light yellow solid. MS (ISP): (M+H) 893.6183

Step 3: was prepared in analogy to example 18, step 3. After purification on silica gel, the title compound (161 mg, 137 μmol) was obtained as light brown solid. MS expected mass: 1057.6174, found mass 1057.6184

Example 20 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-leucyl-N˜1˜-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-aspartamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

was performed in analogy to example 18, step 1

Step 2: (S)-2-((S)-2-(4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanamido)-4-methylpentanamido)-N1-(4-(hydroxymethyl)phenyl)succinamide

Was prepared in analogy to example 18, step 2, using Fmoc-Asn-OH (581 mg, 1.64 mmol, Eq: 4) and Fmoc-Leu-OH (580 mg, 1.64 mmol, Eq: 4) as amino acids. The product (87 mg, 89.4 μmol) was obtained as a light yellow solid. MS expected mass: 875.6136, found mass 875.6133

Step 3: The titled compound was prepared in analogy to example 18, step 3. After purification on silica gel (87 mg, 89.4 μmol) the title compound was obtained as light brown solid. MS expected mass: 1040.6198, found mass 1040.6188

Example 21 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-alanyl-N˜1˜-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-aspartamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

was performed in analogy to example 18, step 1

Step 2: (S)-2-((S)-2-(4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanamido)propanamido)-N1-(4-(hydroxymethyl)phenyl)succinamide

Was prepared in analogy to example 18, step 2, using Fmoc-Asn-OH (581 mg, 1.64 mmol, Eq: 4) and Fmoc-Ala-OH (511 mg, 1.64 mmol, Eq: 4) as amino acids. The product (140 mg, 159 μmol) was obtained as light yellow solid. MS (ISP): (M+H) 834.8 (M+Na) 856.7.

Step 3: The title compound was prepared in analogy to example 18, step 3. After purification on silica gel (169 mg, 152 μmol) it was obtained as light brown solid. MS expected mass: 998.5729, found mass 998.5739

Example 22 N˜2˜-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-asparaginyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]glycinamide

Step 1: Addition of FMOC-4-Aminobenzylalcohol to the 2-chlorotrityl resin

Was performed in analogy to example 18, step 1

Step 2: (S)-2-(4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanamido)-N1-(2-(4-(hydroxymethyl)phenylamino)-2-oxoethyl)succinamide

Was prepared in analogy to example 18, step 2, using Fmoc-Gly-OH (488 mg, 1.64 mmol, Eq: 4) and Fmoc-Asn-OH (581 mg, 1.64 mmol, Eq: 4) as amino acids. The product (140 mg, 162 μmol) was obtained as white solid. MS expected mass: 819.551, found mass 819.5503

Step 3: The title compound was obtained in analogy to example 18, step 3 (176 mg, 161 μmol) as light brown solid. MS expected mass: 984.5572, found mass 984.5489

Example 23 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]glycinamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

Was performed in analogy to example 18, step 1

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-(2-(4-(hydroxymethyl)phenylamino)-2-oxoethylamino)-1-oxo-3-phenylpropan-2-yl)succinamide

Was prepared in analogy to example 18, step 2, using Fmoc-Gly-OH (488 mg, 1.64 mmol, Eq: 4) and Fmoc-Phe-OH (635 mg, 1.64 mmol, Eq: 4) as amino acids. The product (259 mg, 288 μmol) was obtained as white solid. MS expected mass: 852.5765, found mass 852.5754

Step 3: The title compound was obtained in analogy to example 18, step 3. (280 mg, 247 μmol) as light brown solid. MS expected mass: 1017.5827, found mass 1017.5775

Example 24 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl-L-leucyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]glycinamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

Was performed in analogy to example 18, step 1

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-(2-(4-(hydroxymethyl)phenylamino)-2-oxoethylamino)-4-methyl-1-oxopentan-2-yl)succinamide

Was prepared in analogy to example 18, step 2, using Fmoc-Gly-OH (488 mg, 1.64 mmol, Eq: 4) and Fmoc-Leu-OH (580 mg, 1.64 mmol, Eq: 4) as amino acids. The product (240 mg, 278 μmol) was obtained as a light yellow solid. MS expected mass: 818.5921, found mass 818.5921

Step 3: The title compound was prepared in analogy to example 18, step 3. After purification on silica gel, it (194 mg, 177 μmol) was obtained as light yellow solid. MS expected mass: 983.5983 found mass 983.6004

Example 25 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-leucyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-phenylalaninamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

Was performed in analogy to example 18, step 1

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-1-oxo-3-phenylpropan-2-ylamino)-4-methyl-1-oxopentan-2-yl)succinamide

Was prepared in analogy to example 18, step 2, using Fmoc-Phe-OH (635 mg, 1.64 mmol, Eq: 4) and Fmoc-Leu-OH (580 mg, 1.64 mmol, Eq: 4) as amino acids. The product (153 mg, 151 μmol) was obtained as light yellow solid. MS expected mass: 908.6391 found mass 908.637.

Step 3: The title compound was prepared in analogy to example 18, step 3. After purification on silica gel, it (117 mg, 98 μmol) was obtained as white solid. MS expected mass: 1073.6453 found mass 1073.646

Example 26 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-phenylalaninamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

Was performed in analogy to example 18, step 1

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-1-oxo-3-phenylpropan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)succinamide

Was prepared in analogy to example 18, step 2, with Fmoc-Phe-OH (635 mg, 1.64 mmol, Eq: 4) as amino acid. The product (240 mg, 204 μmol) was obtained as light yellow solid. MS expected mass: 942.6234 found mass 942.6218

Step 3: The title compound was prepared analogously to example 18, step 3. After purification on silica gel, it (190 mg, 154 μmol) was obtained as white solid. MS expected mass: 1107.6296 found mass 1107.6287

Example 27 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-leucyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-leucinamide

Step 1: Addition of FMOC-4-aminobenzylalcohol to the 2-chlorotrityl resin

Was performed analogously to example 18, step 1

Step 2: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-4-methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-yl)succinamide

Was prepared in analogy to example 18, step 2, with Fmoc-Leu-OH (1.59 g, 4.5 mmol, Eq: 3) as amino acid. The product (254 mg, 284 μmol) was obtained as white solid. MS expected mass: 874.6547 found mass 874.6527.

Step 3: The title compound was prepared in analogy to example 18, step 3. After purification on silica gel it was obtained as white solid (178 mg, 168 μmol). MS expected mass: 1039.6609 found mass 1039.6588

Example 28 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-alanyl-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-alaninamide

Step 1: {(S)-1-[(S)-1-(4-Hydroxymethyl-phenylcarbamoyl)-ethylcarbamoyl]-ethyl}-carbamic acid 9H-fluoren-9-ylmethyl ester

A solution of Fmoc-Ala-Ala-OH (1 g, 2.61 mmol, Eq: 1.00) and (4-aminophenyl)methanol (483 mg, 3.92 mmol, Eq: 1.5) in THF (20 ml) was treated with EEDQ (970 mg, 3.92 mmol, Eq: 1.5). The solution was stirred over night at room temperature. The mixture was diluted with 10% 2-propanol/ethyl acetate (100 mL) and the solution was washed with KHSO4 5%/K2SO4 10% (2×), water (1×) and brine (1×), dried over MgSO4 and evaporated in vacuo. The residue was sonicated in diethyl ether for several minutes and the solid was collected by filtration to obtain the product (1.27 g, 1.2 mmol) as light brown solid. MS (ISP): (M+H) 488.3

Step 2: (S)-2-Amino-N—[(S)-1-(4-hydroxymethyl-phenylcarbamoyl)-ethyl]-propionamide

The compound was prepared in analogy to example 1 step c to obtain the product (245 mg, 877 μmol) as light yellow solid. MS (ISP): (M+H) 266.3, (M+Na) 288.2 (2M+H) 531.3

Step 3: N1-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propyl)-N4-((S)-1-((S)-1-(4-(hydroxymethyl)phenylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-yl)succinamide

The compound was prepared in analogy to example 16 step 2 (165 mg, 198 μmol) as light brown solid. MS expected mass: 790.5608, found mass 790.5587.

Step 4: The title compound was prepared in analogy to example 18, step 3. After purification on silica gel it was obtained as white solid (99 mg, 98.4 μmol). MS expected mass: 955.567, found mass 955.5651. Example 29 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-isoleucyl-N˜1˜-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-aspartamide

Step 1: (S)-2-[(2S,3S)-2-(9H-Fluoren-9-ylmethoxycarbonylamino)-3-methyl-pentanoylamino]-succinamic acid

2-Chlorotrityl chloride resin (5 g, 7.5 mmol, Eq: 1.00) was swollen in DCM and then treated with a solution of Fmoc-Asn(Trt)-OH (8.95 g, 15.0 mmol, Eq: 2) and Huenig's base (3.88 g, 5.1 ml, 30.0 mmol, Eq: 4) in DCM overnight. The resin was washed with DCM and capped with a solution of 10% Huenig's base in methanol. Coupling of Fmoc-Ile-OH (5.3 g, 15.0 mmol, Eq: 2) with TPTU (4.46 g, 15.0 mmol, Eq: 2) and Huenig's base (3.88 g, 5.1 ml, 30.0 mmol, Eq: 4) according to standard solid phase peptide synthesis. The product was cleaved from the resin with a cocktail of TFA/Water/triisopropylsilane (95/2.5/2.5 v/v/v) for two hours at room temperature. The resin was filtered and the filtrate was concentrated under reduced pressure to a small volume. After trituration with diethyl ether, the product was filtered and dried in vacuum to obtain the product (2.85 g, 5.79 mmol) as white solid. MS expected mass: 467.2056, found mass 467.2056

Step 2: {(1S,2S)-1-[2-Carbamoyl-1-((S)-4-hydroxymethyl-phenylcarbamoyl)-ethylcarbamoyl]-2-methyl-butyl}-carbamic acid 9H-fluoren-9-ylmethyl ester

The compound was prepared in analogy to example 28 step 1 (620 mg, 336 μmol) as light yellow solid.

Step 3: (S)-2-((2S,3S)-2-Amino-3-methyl-pentanoylamino)-N*1*-(4-hydroxymethyl-phenyl)-succinamide

The compound was prepared in analogy to example 1 step c (100 mg, 228 μmol) as light yellow solid.

Step 4: (S)-2-((2S,3S)-2-(4-(3-((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)propylamino)-4-oxobutanamido)-3-methylpentanamido)-N1-(4-(hydroxymethyl)phenyl)succinamide

The compound was prepared in analogy to example 16 step 2 (89 mg, 91.4 μmol) as light yellow solid.

Step 5: The compound from the previous step was reacted to the title compound analogously to example 18, step 3. After purification on silica gel, it (42 mg, 36.3 μmol) was obtained as a light brown solid. MS expected mass: 1040.6198, found mass 1040.6177

Example 30 N-[4-({3-[(3beta)-cholest-5-en-3-yloxy]propyl}amino)-4-oxobutanoyl]-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-D-lysinamide

The compound was prepared in analogy to example 16 step 1, starting with Fmoc-D-Lys(Boc)-OH, (158 mg, 116 μmol) as light brown solid. MS (ISP): (M+H) 1362.8 (M+Na) 1383.8

Example 31 N-{15-[(3beta)-cholest-5-en-3-yloxy]-4,15-dioxo-8,11-dioxa-5,14-diazapentadecan-1-oyl}-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

The title compound was prepared analogous to example 16 using a cholesterol-oligo-PEG derivative in step 2 of the synthesis. MS (ISP): (M+H) 1479.8

The necessary cholesterol-PEG intermediate N-[2-(2-{2-[(3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-ethoxy}-ethoxy)-ethyl]-succinamic acid for step 2 was prepared as follows:

Step a: {2-[2-(2-Amino-ethoxy)-ethoxy]-ethyl}-carbamic acid (3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester

A solution of cholesteryl chloroformate (1 g, 2.23 mmol) in 25 mL dichloromethane was added dropwise under stirring to a solution of 2,2′-(ethylenedioxy)bis-(ethylamine) (495 mg, 3.34 mmol) in 75 mL dichloromethane. The reaction was stirred overnight at room temperature. The reaction was diluted with dichloromethane and extracted with water. The organic extract was dried over anhydrous MgSO4 dihydrate, filtered and evaporated. After purification on amino-modified silica gel (eluent: MeCl2->MeCl2/MeOH=975:25 v/v) the product (615 mg) was obtained as a white, waxy solid. MS (ISP): (M+H) 561.5

Step b: N-[2-(2-{2-[(3S,8S,9S,10R,13R,14S,17R)-17-((R)-1,5-Dimethyl-hexyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxycarbonylamino]-ethoxy}-ethoxy)-ethyl]-succinamic acid

The amine from step a (480 mg, 0.856 mmol) and triethylamine (0.13 mL, 0.94 mmol) were dissolved in 5 mL dichloromethane. After adding succinic anhydride (90 mg, 0.9 mmol) the solution was stirred overnight at room temperature. TLC check showed still some starting material. More succinic anhydride (20 mg, 0.2 mmol) was added. After stirring the reaction for another 3 hours at room temperature, it was diluted with dichloromethane and washed with a 5% KHSO4/10% K2SO4 mixture. The organic extract was dried over anhydrous MgSO4-dihydrate, filtered and evaporated in vacuo to obtain the desired acid (490 mg, 0.667 mmol). MS (ISP): (M+H) 661.5

Example 32 N-{30-[(3beta)-cholest-5-en-3-yloxy]-4,30-dioxo-8,11,14,17,20,23,26-heptaoxa-5,29-diazatriacontan-1-oyl}-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

The title compound was prepared analogous to example 16 using a cholesterol-PEG derivative in step 2 of the synthesis. MS (ISP): (M+H) 1699.9

The necessary cholesterol-PEG intermediate 1-[(3beta)-cholest-5-en-3-yloxy]-1,27-dioxo-5,8,11,14,17,20,23-heptaoxa-2,26-diazatriacontan-30-oic acid for step 2 was prepared as follows:

Step a: tert-butyl [25-({(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl}oxy)-25-oxo-3,6,9,12,15,18,21-heptaoxa-24-azapentacos-1-yl]carbamate

Cholesteryl chloroformate (476 mg, 1.06 mmol) and triethylamine (155 uL, 1.113 mmol) were dissolved in 5 mL dichloromethane. Then a solution of alpha-amino-omega-boc-amino-octa(ethylene glycol) (497 mg, 1.06 mmol) dissolved in 1 mL dichloromethane was added. The solution was stirred over night at room temperature and diluted with dichloromethane and extracted with a KHSO4 5%/K2SO4 10% aqueous mixture. The organic extract was dried over anhydrous MgSO4, filtered and evaporated in vacuo. After purification on silica gel (eluent: MeCl2/MeOH=975:25->95:5 v/v) the product (530 mg, 0.571 mmol) was obtained as a colorless oil. MS (ISP): (M+NH4) 898.7

Step b: 1-[(3beta)-cholest-5-en-3-yloxy]-1,27-dioxo-5,8,11,14,17,20,23-heptaoxa-2,26-diazatriacontan-30-oic acid

The previous Boc derivative (450 mg, 0.511 mmol) was dissolved in HCl 4M in dioxane (10.2 mL, 40.9 mmol). The solution was stirred at room temperature for 40 min. The solvent was removed in vacuo and the remaining white solid was dissolved in 5 mL dichloromethane and treated with triethylamine (32 uL, 0.229 mmol) and succinic anhydride (11.5 mg, 0.114 mmol) overnight. More succinic anhydride (11 mg, 0.11 mmol, 0.2 equiv.) was added and after 60 min the reaction was diluted with dichloromethane and washed with KHSO4 5%/K2SO4 10% buffer. The organic extract was dried over MgSO4 anhydrous, filtered and evaporated to obtain 390 mg of the desired product. MS (ISP): (M+H) 881.7

Example 33 N-{66-[(3beta)-cholest-5-en-3-yloxy]-4,66-dioxo-8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62-nonadecaoxa-5,65-diazahexahexacontan-1-oyl}-L-phenylalanyl-N˜6˜-[(4-methoxyphenyl)(diphenyl)methyl]-N-[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-lysinamide

The title compound was prepared analogous to example 16 using a cholesterol-PEG derivative in step 2 of the synthesis. MS (ISP): (M+H) 2228.1

The necessary cholesterol-PEG intermediate 1-[(3beta)-cholest-5-en-3-yloxy]-1,63-dioxo-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59-nonadecaoxa-2,62-diazahexahexacontan-66-oic acid for step 2 was prepared as follows:

Step a: (3beta)-cholest-5-en-3-yl (59-amino-3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57 nonadecaoxanonapentacont-1-yl)carbamate

Alpha, omega-bis-amino 20(ethylene glycol) (538 mg, 0.6 mmol) and triethylamine (92 uL, 0.66 mmol) were dissolved in 15 mL dry dichloromethane. A solution of cholesteryl chloroformate (270 mg, 0.6 mmol) in 2 mL dry dichloromethane was added dropwise at room temperature. The solution was stirred overnight, then concentrated in vacuo to a small volume and purified directly on silica gel (eluent: MeCl2/MeOH=95:5->9:4->4:1 v/v) to obtain the product (350 mg, 0.254 mmol) as a waxy solid. MS (ISP): (M+H) 1309.9

Step b: 1-[(3beta)-cholest-5-en-3-yloxy]-1,63-dioxo-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59-nonadecaoxa-2,62-diazahexahexacontan-66-oic acid

The amine from step a (329 mg, 0.251 mmol), succinic anhydride (26.4 mg, 0.264 mmol) and triethylamine (40 uL, 0.286 mmol) were dissolved in 5 mL dry dichloromethane. After adding more triethylamine (40 uL, 0.286 mmol), the solution (pH>8) was stirred overnight at room temperature. The reaction was diluted with dichloromethane and washed twice with a KHSO₄ 5%/K₂SO₄ 10% aqueous mixture. The organic extract was dried over anhydrous MgSO₄, filtered and evaporated to obtain the product (260 mg, 0.175 mmol) as a colorless, waxy solid. MS (ISP): (M+NH4) 1408.9

Example 34 General Procedure for the Preparation of RNA Conjugates Materials

Dimethyl sulfoxide (DMSO), N,N-Diisopropylethylamine (DIPEA) and sodium acetate solution (3 M, pH 5.2) were purchased from Sigma Aldrich Chemie GmbH (Traufkirchen, Germany).

Triethylammonium acetate (TEAA) (2.0 M, pH 7.0) and Acetonitrile (ACN, HPLC quality) for RP-HPLC were purchased from Biosolve (Valkenswaard, Netherlands).

Ethanol (EtOH, p.a.) was purchased from Merck (Darmstadt, Germany). Purified water from a Optilab HF (Membra Pure, Germany) system was used.

Resource RPC 3 mL column (10×0.64 cm; 15 μm particle size) was purchased from GE Healthcare (Freiburg, Germany).

HPLC purification was accomplished using an ÄKTA Explorer 100 system (GE Healthcare).

Synthesis of Amino-Modified RNA

RNA equipped with a hexylaminolinker at the 5′-end of the sense strand was produced by standard phosphoramidite chemistry on solid phase at a scale of 1215 μmol using an ÄKTA Oligopilot 100 (GE Healthcare, Freiburg, Germany) and controlled pore glass as solid support (Prime Synthesis, Aston, Pa., USA). RNA containing 2′-O-methyl nucleotides were generated employing the corresponding phosphoramidites, 2′-O-methyl phosphoramidites and TFA-hexylaminolinker amidite (Sigma-Aldrich, SAFC, Hamburg, Germany). Cleavage and deprotection as well as purification was achieved by methods known in the field (Wincott F., et al, NAR 1995, 23, 14, 2677-84).

The amino-modified RNA was characterized by anion exchange HPLC (purity: 96.1%) and identity was confirmed by ESI-MS ([M+H]1+ calculated: 6937.4; [M+H] 1+measured: 6939.0.

Sequence: 5′-(NH2C6)GGAAUCuuAuAuuuGAUCcAsA-3′; u, c: 2′-O-methyl nucleotides of corresponding RNA nucleotides, s: phosphorthioate.

General Experimental Conjugation Procedure

The title compounds of examples 1-33 were coupled via the amino-modified RNA according the following procedure:

RNA equipped with a C-6 aminolinker at the 5′-end (16.5 mg, 1 equivalent) is dissolved in 500 μL DMSO and 150 μL water. The p-Nitrophenylcarbonate derivative (10 equivalents) dissolved in 1 mL DMSO is added followed by 8 μL DIPEA. The reaction mixture is shaken at 35° C. in the dark and monitored using RP-HPLC (Resource RPC 3 mL, buffer: A: 0.1M TEAA in water, B: 0.1M TEAA in 95% ACN, gradient: 3% B to 100% B in 20 CV). Once the reaction is gone to completion the RNA conjugate is precipitated using sodium acetate (3 M) in EtOH at −20° C. For examples lacking a MMT protecting group in the dipeptide motif the corresponding conjugates are purified using the conditions described above. Pure fractions are pooled and the material is precipitated using sodium acetate/EtOH to give the desired RNA conjugate.

RNA conjugates containing a MMT protecting group in the dipeptide sequence are further processed according to the procedure given below.

General Procedure for MMT Cleavage

The crude RNA conjugate pellet is dissolved in 500 μL water and 1.5 mL sodium acetate buffer (3 M, pH 5.2 or 0.1M, pH 4.0). The solution is shaken for 2 days at 30° C. The reaction mixture is monitored using RP-HPLC (Resource RPC 3 mL, buffer: A: 0.1M TEAA in water, B: 0.1M TEAA in 95% ACN, gradient: 3% B to 100% B in 20 CV). After complete cleavage of the MMT protecting group the RNA conjugate is directly purified using the conditions just mentioned above. Pure fractions are pooled and the desired conjugate is precipitated using sodium acetate/EtOH.

As a control a RNA conjugate lacking the dipeptide motif was synthesized. For this purpose cholesterol was attached to the 5′-end via a linker described in the literature (Nature Biotech, 2007, 25, 1149). This conjugate is referred to as “non-cleavable”.

All the RNA conjugates were analyzed by RP HPLC for purity and identity was confirmed by ESI MS (negative mode). Briefly, RP-HPLC was performed on a Dionex Ultimate system (Dionex, Idstein, Germany) equipped with a XBridge C₁₈ column (2.5×50 mm, 2.5 μm particle size, Waters, Eschbom, Germany) at 65° C. column temperature. Gradient elution was performed using 100 mM hexafluoroisopropanol (HFIP) and 16 mM triethylamine in 1% methanol as eluent A and in 95% methanol as eluent B (1% B to 18% B in 30 minutes). UV detection was recorded at 260 nm. For mass spectrometric analysis a ThermoFinnigan LCQ DecaXP ESI-MS system with micro-spray source and ion trap detector was coupled online to the HPLC system.

Examples of specific compounds of formula (IIa) are disclosed in table 1. The resulting compounds are referred to “di-peptide containing cholesterol siRNA conjugates”, wherein the specific di-peptide containing cholesterol siRNA conjugates are further referred to as “Title compound example X—(NHC6)-(siRNA sequence)” and “siRNA with Title compound of Example X”.

siRNA Preparation

Antisense sequence: 5′-uuGGAUcAAAuAuAAGAuUCcscsU-3′

u, c: 2′-O-methyl nucleotides of corresponding RNA nucleotides, s: phosphorthioate

The di-peptide containing cholesterol siRNA conjugates directed against the apolipoprotein B mRNA were generated by mixing an equimolar solution of complementary strands in annealing buffer (20 mM sodium phosphate, pH 6.8; 100 mM sodium chloride), heated in a water bath at 80-85° C. for 3 minutes and cooled to room temperature over a period of 3-4 hours. Duplex formation was confirmed by native gel electrophoresis.

All prepared di-peptide containing cholesterol siRNA conjugates are listed in table 2.

TABLE 1 Di-peptide containing cholesterol siRNA conjugates (5′-3′) and analytical data. Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; A phosphorothioate linkages is symbolized with a lower case “s”. (NHC6) is the aminohexyl linker incorporatd at the 5′-end of the sense strand. Title compound from Mol Mol Purity example mass mass (%) No. calc. exp. (RP) 16 (Title compound Ex 16)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7885.7 7887.5 94.4 31 (Title compound Ex 16)(NHC6)GGAAUCuuAuAuuuGAUCcASA 8003.8 8003.3 97.3 33 (Title compound Ex 33)(NHC6)GGAAUCuuAuAuuuGAUCcASA 8752.7 8752.4 97.6 32 (Title compound Ex 32)(NHC6)GGAAUCuuAuAuuuGAUCcASA 8223.1 8226.5 97.3 17 (Title compound Ex 17)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7870.7 7873.5 90.6 30 (Title compound Ex 30)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7884.8 7888.8 95.2 27 (Title compound Ex 27)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7840.0 7840.0 94.8 28 (Title compound Ex 28)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7755.4 7754.9 93.2 29 (Title compound Ex 29)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7840.4 7839.9 87.2 1 (Title compound Ex 1) (NHC6)GGAAUCuuAuAuuuGAUCcASA 7931.1 7935.2 98.2 2 (Title compound Ex 2)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7992.2 7995.0 96.7 3 (Title compound Ex 3)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7911.1 7913.8 98.2 4 (Title compound Ex 4)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7955.1 7958.5 98.0 5 (Title compound Ex 5)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7920.5 7923.9 97.2 6 (Title compound Ex 6)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7936.1 7939.6 98.5 7 (Title compound Ex 7)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7904.2 7905.5 95.1 8 (Title compound Ex 8)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7904.2 7908.7 98.8 9 (Title compound Ex 9)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7904.2 7906.7 98.7 10 (Title compound Ex 10)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7918.2 7921.0 95.4 11 (Title compound Ex 11)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7902.0 7901.5 98.7 12 (Title compound Ex 12)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7934.54 7936.5 94.4 13 (Title compound Ex 13)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7916.09 7917.9 96.5 14 (Title compound Ex 14)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7886.07 7888.3 94.9 24 (Title compound Ex 24)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7781.8 7783.4 97.2 23 (Title compound Ex 23)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7815.8 7817.3 95.2 22 (Title compound Ex 22)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7781.8 7783.9 90.5 26 (Title compound Ex 26)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7905.9 7907.0 96.4 25 (Title compound Ex 25)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7871.9 7873.2 96.1 20 (Title compound Ex 20)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7840.7 7840.0 95.9 19 (Title compound Ex 19)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7857.8 7856.6 97.3 18 (Title compound Ex 18)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7741.6 7741.1 93.9 21 (Title compound Ex 21)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7798.6 7797.8 87.6 15 (Title compound Ex 15)(NHC6)GGAAUCuuAuAuuuGAUCcASA 7927.1 7926.8 97.2

TABLE 2 Di-peptide containing cholesterol siRNA conjugates. The last entry (SEQ ID NO pair 266/154) represents a siRNA conjugate lacking the di-peptide motif. Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; A phosphorothioate linkages is symbolized with a lower case “s”. (NHC6) is the aminohexyl linker incorporated at the 5′-end of the sense strand. SEQ ID SEQ ID No Sense sequence (5′-3′) No Antisense sequence (5′-3′) — (Title compound Ex 16)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 31)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 33)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 32)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 17)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 30)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 27)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 28)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 29)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 1)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 2)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 3)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 4)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 5)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 6)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 7)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 8)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 9)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 10)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 11)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 12)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 13)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 14)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 24)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 23)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 22)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 26)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 25)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 20)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 19)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 18)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 21)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA — (Title compound Ex 15)(NHC6) 154 uuGGAUcAAAuAuAAGAuUCcscsU GGAAUCuuAuAuuuGAUCcAsA 266 (Chol)GGAAUCuuAuAuuuGAUCcAcA 154 uuGGAUcAAAuAuAAGAuUCcscsU

Example 35 In Vivo Experiments Co-Administration of Di-Peptide Containing Cholesterol siRNA Conjugates and Delivery Polymer In Vivo

Six to eight week old mice (strain C57BL/6 or ICR, ˜18-20 g each) were obtained from Harlan Sprague Dawley (Indianapolis Ind.). Mice were housed at least 2 days prior to injection. Feeding was performed ad libitum with Harlan Teklad Rodent Diet (Harlan, Madison Wis.).

Mice (n=3 per group) were injected with a mixture of 0.2 mL solution of delivery polymer and 0.2 ml di-peptide containing cholesterol siRNA conjugates. The injected dose was, unless otherwise stated, 15 mg/kg for the delivery polymer and 0.1 mg/kg with respect to the di-peptide containing cholesterol siRNA conjugates. Solutions were injected by infusion into the tail vein. 48 hours post injection serum ApoB levels were measured relative to isotonic glucose treated animals according to the procedure below.

Serum ApoB Levels Determination.

Mice were fasted for 4 h before serum collection by submandibular bleeding. Serum ApoB protein levels were determined by standard sandwich ELISA methods. Briefly, a polyclonal goat anti-mouse ApoB antibody and a rabbit anti-mouse ApoB antibody (Biodesign International) were used as capture and detection antibodies respectively. An HRP-conjugated goat anti-rabbit IgG antibody (Sigma) was applied afterwards to bind the ApoB/antibody complex. Absorbance of tetramethyl-benzidine (TMB, Sigma) colorimetric development was then measured by a Tecan Safire2 (Austria, Europe) microplate reader at 450 nm.

In FIG. 1 various di-peptide containing cholesterol siRNA conjugates were benchmarked against the same siRNA conjugated to cholesterol but lacking the cleavable motif elaborated earlier in this section. The effect of this siRNA conjugate (SEQ ID NO pair 266/154, “non-cleavable control”) on serum ApoB levels was set to 1 in order to evaluate the influence of the di-peptide containing conjugates relative to the non-cleavable control. Substituting the initially used Phe-Lys motif (siRNA with Title compound of Example 16) with the corresponding D-amino acids (siRNA with Title compound of Example 14) or just replacing the Lys with the unnatural enantiomer (siRNA with Title compound of Example 30) yielded ApoB reduction less pronounced or equivalent to the non-cleavable control siRNA. Replacing Lys by Gly (siRNA with Title compound of Example 23) or Phe by p-Methoxyphenylalanine (siRNA with Title compound of Example 13) reduced the potency compared to siRNA with Title compound of Example 16. Other di-peptide motifs containing siRNA conjugates were shown to be as efficacious as the original Phe-Lys containing conjugate.

FIG. 2 summarizes di-peptide containing cholesterol siRNA conjugates that were as efficacious or had improved efficacy compared to siRNA with Title compound of Example 16 consisting of the Phe-Lys motif. All these conjugates were significantly more active compared to the “non-cleavable” cholesterol siRNA conjugate SEQ ID NO pair 266/154. The best performing di-peptide containing cholesterol siRNA conjugates had a fluorine modified phenyl ring in the Phy-Lys motif (siRNA with Title compound of Example 8, siRNA with Title compound Example 9) or had the phenylalanine substituted with beta-phenylalanine (siRNA with Title compound of Example 11) or a derivative thereof (siRNA with Title compound of Example 10).

Since di-peptide containing cholesterol siRNA conjugates with di-peptide motifs consisting of D-amino acids are performing equal to the non-cleavable control conjugate it is conceivable that the other di-peptide sequences are indeed cleaved by a protease activity in vivo. However, given the broad acceptance of different amino acids and derivatives thereof it is likely that more than one enzyme is participating in the cleavage reaction as suggested in the literature (Bioconjugate Chem. 2002,13,855).

As shown in FIG. 3, the incorporation of a Cathepsin cleavable di-peptide motif (in this case Phe-Lys, siRNA with Title compound of Example 16) between the siRNA and the small molecule ligand cholesterol boosts the potency of the siRNA conjugate compared to the straight cholesterol siRNA conjugate (SEQ ID NO pair 266/154). Further spacing of the cholesterol ligand from the di-peptide motif by means of PEG based linkers diminishes the potency proportional to the length of the PEG linker.

In FIG. 4 the polymer dose was kept constant at 15 mg/kg. The siRNA dose was titrated and the effect on serum ApoB content was measured. The Di-peptide containing cholesterol siRNA conjugates containing the Phe-Lys (F-K) motif was significantly more potent compared to the control conjugate lacking the di-peptide sequence.

Example 36 2′-Modified Oligoribonucleotide Synthesis

Oligoribonucleotides were synthesized according to the phosphoramidite technology on solid phase. Depending on the scale either an ABI 394 synthesizer (Applied Biosystems) or an AKTA oligopilot 100 (GE Healthcare, Freiburg, Germany) was used. Syntheses were performed on a solid support made of controlled pore glass (CPG, 520 Å, with a loading of 75 mol/g, obtained from Prime Synthesis, Aston, Pa., USA). All 2′-modified RNA phosphoramidites as well as ancillary reagents were purchased from SAFC (Hamburg, Germany). Specifically, the following 2′-O-Methyl phosphoramidites were used: (5′-O-dimethoxytrityl-N⁶-(benzoyl)-2′-O-methyl-adenosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, 5′-O-dimethoxytrityl-N⁴-(acetyl)-2′-O-methyl-cytidine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, (5′-O-dimethoxytrityl-N²-(isobutyryl)-2′-O-methyl-guanosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, and 5′-O-dimethoxytrityl-2′-O-methyl-uridine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite. The 2′-Deoxy-2′-fluoro-phosphoramidites carried the same protecting groups as the 2′-O-methyl RNA amidites. All amidites were dissolved in anhydrous acetonitrile (100 mM) and molecular sieves (3 Å) were added. To generate the 5′-phosphate the 2-[2-(4,4′-Dimethoxytrityloxy)ethylsulfonyl]ethyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite from Glen Research (Sterling, Va., USA) was used. In order to introduce the C-6 aminolinker at the 5′-end of the oligomers the 6-(Trifluoroacetylamino)-hexyl-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite from Thermo Fisher Scientific (Milwaukee, Wis., USA) was employed. The 5′-modifications were introduced without any modification of the synthesis cycle. 5-Ethyl thiotetrazole (ETT, 500 mM in acetonitrile) was used as activator solution. Coupling times were 6 minutes. In order to introduce phosphorothioate linkages a 50 mM solution of 3-((Dimethylamino-methylidene)amino)-3H-1,2,4-dithiazole-3-thione (DDTT, obtained from AM Chemicals, Oceanside, Calif., USA) in anhydrous Acetonitrile/pyridine (1:1 v/v) was employed.

Example 37 Cleavage and Deprotection of Support Bound Oligomer

After finalization of the solid phase synthesis, the dried solid support was transferred to a 15 mL tube and treated with concentrated aqueous ammonia (Aldrich) for 18 hours at 40° C. After centrifugation the supernatant was transferred to a new tube and the CPG was washed with aqueous ammonia. The combined solutions were evaporated and the solid residue was reconstituted in buffer A (see below).

Example 38 Purification of Oligoribonucleotides

Crude oligomers were purified by anionic exchange HPLC using a column packed with Source Q15 (GE Helthcare) and an AKTA Explorer system (GE Helthcare). Buffer A was 10 mM sodium perchlorate, 20 mM Tris, 1 mM EDTA, pH 7.4 (Fluka, Buchs, Switzerland) and contained 20% Acetonitrile and buffer B was the same as buffer A with the exception of 500 mM sodium perchlorate. A gradient of 22% B to 42% B within 32 column volumes (CV) was employed. UV traces at 280 nm were recorded Appropriate fractions were pooled and precipitated with 3M NaOAc, pH=5.2 and 70% Ethanol. Finally, the pellet was washed with 70% Ethanol.

Example 39 Annealing of Oligoribonucleotides to Generate siRNA

Complementary strands were mixed by combining equimolar RNA solutions. The mixture was lyophilized and reconstituted with an appropriate volume of annealing buffer (100 mM NaCl, 20 mM sodium phosphate, pH 6.8) to achieve the desired concentration. This solution was placed into a water bath at 95° C. which was cooled to rt within 3 h.

Example 40 In Vitro Activity of siRNAs Devoid of 2′-OH Residues

In order to investigate if siRNAs lacking any 2′-OH residues show potent in vitro knock down activity, we tested a panel of EGFP mRNA-targeted siRNAs with different 2′-modification chemistries (SEQ ID pairs 31/32 to 149/150, and see Table 3 for examples). The siRNAs were screened for sense and antisense activity with the Dual-Glo® Luciferase Assay System (Promega) using the psiCHECK2 vector (Promega) in COS7 cells (DSMZ, Braunschweig, Germany, cat. No. ACC-60). To address the silencing activity conferred by sense and antisense strand we cloned each corresponding 19mer target site sequence as separate psiCHECK2 construct (psiCHECK2-AT for antisense activity, psiCHECK2-ST for sense activity) into the multiple cloning region located 3′ to the translational stop codon of the synthetic Renilla luciferase. By using Lipofectamine 2000 (Invitrogen GmbH, Karlsruhe, Germany, cat. No. 11668-019) COS7 cells were co-transfected with vector construct and 3 nM of the corresponding siRNA complementary to the cloned target site. Successful siRNA-mediated silencing was determined 24 hours after transfection via the activity of the renilla luciferase normalized to firefly luciferase levels to take transfection efficiency into account (see FIG. 5 a for antisense activity and FIG. 5 b for sense activity).

Table 3: Exemplary siRNA sequences and chemical modifications used for determination of in vitro knock down activity dependent on 2′-modifications. Reference duplices and selected examples of corresponding modification variants used in this study. Xf indicates a 2′-fluoro modification of the nucleotide X, small letters indicate a 2′-O-methyl modification, underlined letters indicate a DNA nucleotide, all other capital letters indicate ribonucleotides. The letter “p” indicates a 5′-phosphate.

RNA duplices unmod 5′- UGCCCAUCCUGGUCGAGCUTT -3′ 3′- TTACGGGUAGGACCAGCUCGAp -5′ F/OMe 5′- UfgCfcCfaUfcCfuGfgUfcGfaGfcUfTsT -3′ 3′- TsTaCfgGfgUfaGfgAfcCfaGfcUfcGfap -5′ F/DNA 5′- UfGCfCCfAUfCCfUGfGUfCGfAGfCUfTsT -3′ 3′- TsTACfGGfGUfAGfGAfCCfAGfCUfCGfAp -5′ DNA/OMe 5′- UgCcCaUcCuGgUcGaGcUTsT -3′ 3′- TsTaCgGgUaGgAcCaGcUcGap -5′

It was found that the 5 most potent modified siRNAs (≧60% knock-down) were designed in an alternating 2′-fluoro/2′-O-methyls (2′F/2′-OMe) pattern. While conferring antisense activity, this chemistry fully eliminated the activity of the corresponding sense strands, as shown by lack or minimal renilla luciferase activity for all tested 2′F/2′-OMe variants.

We concluded that such 2′F/2′-OMe pattern is promoting the siRNA's intended antisense strand activity while undesired off-target effects coming from the sense strand are fully suppressed. This design is specifically preferable for siRNAs, that come with the need for protection against 2′O-directed nucleolytic cleavage.

Example 41 Detection of DNAse II-Sensitive Sites by In Vitro Assay

An ion pairing (IP) reversed phase (RP) high performance liquid chromatography (HPLC) coupled to an electrospray ionization (ESI) mass spectrometry (MS) or an anion exchange (AEX)-HPLC based method was established to test the in vitro stability of selected single and double stranded RNAs.

Method description: For stability analysis a 10 μM solution of either single stranded or double stranded RNA was incubated at 37° C. in 5 mM sodium acetate buffer solution (pH 4.5) containing 0.8 or 8 units DNase II (from bovine spleen, Type V, Sigma Aldrich). The incubation reaction was stopped by adding a 100 mM triethyl ammonium acetate (TEAA) solution, shifting the pH to 7 and inactivating the DNase II enzyme. Analysis was done by either LC/MS combined with UV-detection or by AEX-HPLC with UV-detection. UV-detection traces at 260 nm were used for quantitative analysis, MS data served for cleavage site identification within the RNA sequence.

-   A. IP-RP-HPLC was done employing a Waters XBridge C₁₈ column (2.5×50     mm, 2.5 μm particle size) at 65° C. column temperature. Gradient     elution was performed using 100 mM hexafluoroisopropanol (HFIP) and     16 mM triethylamine in 1% methanol as eluent A and composition A in     95% methanol as eluent B. A gradient from 1% B to 18% B in 30     minutes was employed. -   B. AEX-HPLC was performed on a Dionex DNA Pac200 column (4×250 mm)     at 50° C. using a 20 mM phosphate buffer containing 10% ACN at     pH=11. Eluent B contained 1 M NaBr in eluent A. A gradient from 25     to 62% B in 18 minutes was employed.

TABLE 4 Duplexes and the remaining intact strands evaluated for their stability against DNase II. Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; Upper case letters A, C, G, U followed by “f” indicates a 2′-fluoro nucleotide. Lower case “p” indicates a 5′-phosphate. (invdT) represents an inverted deoxythimidine (3′-3′-linked). A phosphorothioate linkages is symbolized with a lower case “s”. dT is deoxy- thimidine. (NHC6) is the aminohexyl linker incorporated at the 5′-end of the sense strand. % Intact % Intact SEQ strand SEQ strand ID Sense strand after 6 ID Antisense strand after 6 NO sequence (5′-3′) hours NO sequence (5′-3′) hours 157 GGAuGAAGuGGAGAuuAGud   0 158 ACuAAUCUCcACUUcAUCCd   0, 1 TsdT TsdT 160 (NH2C6)GfgAfuGfaAfgUfgGfa 101 159 pasCfuAfaUfcUfcCfaCfuUfcAf  97 GfaUfuAfgUf(invdT) uCfc(invdT) 165 (NH2C6)GfcAfaAfgGfcGfuGfc 103 166 puGfaGfuUfgGfcAfcGfcCfuUfu 103 CfaAfcUfcAf(invdT) Gfc(invdT) 167 (NH2C6)GcAAAGGcGuGccAA  56 168 UGAGUUGGcACGCCUUUGC  49 cucAdTsdT dTsdT 169 (NH2C6)GGAUfCfAUfCfUfCf  64 170 GUfAAGACfUfUfGAGAUfGA  54 AAGUfCfUfUfACfdTsdT UfCfCfdTsdT 153 GGAAUCuuAuAuuuGAUCcAs   0, 1 154 uuGGAUcAAAuAuAAGAuUC   0, 1 A cscsU 173 (NH2C6)UfgAfcCfaCfaGfuCfg 102 174 pusUfuAfaUfcCfgAfcUfgUfgGf 102 GfaUfuAfaAf(invdT) uCfa(invdT) 175 (NH2C6)uGAccAcAGucGGAu   0, 4 176 puUuAAUCCGACUGUGGucA   0, 3 uAAAdTsdT dTsdT 175 (NH2C6)uGAccAcAGucGGAu   6 177 UUuAAUCCGACUGUGGUcA   3 uAAAdTsdT dTsdT

CONCLUSIONS

A. RNA strands containing at least one 2′-OH nucleotide (e.g. both strands of SEQ ID NO piar 157/158) are rapidly degraded via a cyclic pentavalent intermediate, leading to 2′-3′ cyclic phosphates at the 5′-cleavage product. The formation of the pentavalent intermediate can be inhibited using nucleotides lacking a 2′-OH group, like e.g. 2′-deoxy, 2′-OMe or 2′-F. B. Additionally, RNA is degraded via a 5′-exonucleolytic pathway, that is independent from the 2′-modification on the 5′-terminal nucleotides. This degradation pathway can be inhibited using 5′-terminal non-nucleotide moieties, like e.g. a C6-aminolinker (e.g. SEQ ID NO 160 in SEQ ID NO pair 160/159 or SEQ ID NO 165 in SEQ ID NO pair 165/166) or a phosphorothioate at the first internucleotide linkage (e.g. SEQ ID NO 160 in SEQ ID NO pair 160/159). C. A 5′-phosphate group slows down the exonucleolytic cleavage kinetics, but can not fully block the degradation starting at this end (e.g. SEQ ID NO 160 in SEQ ID NO pair 160/159). This is most probably due to the cleavage of the 5′-phosphate by either phosphatases or by an inherent phosphatase activity of the DNase II enzyme. D. The best protection for RNA strands was achieved with oligonucleotides containing no 2′-OH nucleotide within the strand, starting with a 2′-OMe nucleotide at the 5′-end connected by a phosphorothioate linkage to the second nucleotide (e.g. SEQ ID NO 173 in SEQ ID NO pair 173/174). Other terminal non-2′-OH nucleotides also protect against the 5′-exo degradation, but to a lower extent compared to the 2′-OMe modification (refer to Table 9)

Example 42 In Vivo Knock Down Activity of siRNAs Devoid of 2′-OH Residues

In vivo experiments were conducted with mice injected with Factor VII (FVII)-targeting siRNAs (SEQ ID NO pairs 179/166 and 180/168, see Table 5) co-administered with DPC-GalNac.

TABLE 5 a Sequences of siRNAs for in vivo experiment. Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; Upper case letters A, C, G, U followed by “f” indicates a 2′-fluoro nucleotide. Lower case “p” indicates a 5′- phosphate. (invdT) represents an inverted deoxythimidine (3′-3′-linked). A phosphorothioate linkages is symbolized with a lower case “s”. dT is deoxythimidine. (NHC6) is the aminohexyl linker incorporated at the 5′-end of the sense strand. GalNAc refers to the structure in formula (IV). SEQ ID SEQ ID NO pair NOs Sequence 5′->3′ 179/166 179 GalNAc-(NHC6)- GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 166 puGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 180/168 180 GalNAc-(NHC6)-GcAAAGGcGuGccAAcucAdTsdT 168 UGAGUUGGcACGCCUUUGCdTsdT

A FVII siRNA with an alternating 2′-OMe/2′-F pattern on sense and antisense strand was generated with a 5′-terminal 2′-OMe nucleotide on the antisense and a 5′-terminal 2′-F strand on the sense strand. Both strands are protected by an inv(dT) at the 3′-terminal overhang. The antisense strand was bearing a 5′-phosphate group to maintain activity of the siRNA. The sense strand was conjugated to a GalNAc-palmitoyl construct at its 5′ end for targeting to hepatocytes by the asialyloglycoprotein-receptor. siRNA (2.5 mg/kg) was co-administered with GalNAc-targeted PBAVE (15 mg/kg) in mice.

FVII mRNA measurements were done from liver homogenates using QuantiGene 1.0 branched DNA (bDNA) Assay Kit (Panomics, Fremont, Calif., USA, Cat-No: QG0004).

At necropsy 1-2 g liver tissue was snap frozen in liquid nitrogen. Frozen tissue was powderized with mortar and pistil on dry ice. 15-25 mg of tissue was transferred to a chilled 1.5 mL reaction tube, 1 mL 1:3 Lysis Mixture prediluted in MilliQ water and 3.3 μL Proteinase K(50 μg/μL) was added and tissue was lysed by several seconds ultrasound sonication at 30-50% power (HD2070, Bandelin, Berlin, Germany). Lysates were stored at −80° C. until analysis. For mRNA analysis lysate was thawed and digested with Proteinase K for 15 min at 1000 rpm in a thermomixer at 65° C. (Thermomixer comfort, Eppendorf, Hamburg, Germany). FVII and GAPDH mRNA levels were determined using QuantiGene 1.0 bDNA Assay Kit reagents according to the manufacturer's recommendations. FVII mRNA expression was analyzed using 20 μL lysate and a mouse FVII probe set. GAPDH mRNA expression was analysed using 40 μL lysate and rattus norwegicus probe sets shown to be cross-react with mice (sequences of probesets see above). As assay readout the chemiluminescence signal at end of the assay was measured in a Victor 2 Light luminescence counter (Perkin Elmer, Wiesbaden, Germany) as relative light units (RLU). The signal for FVII mRNA was divided by signal for GAPDH mRNA from the same lysate Values are reported as FVII mRNA expression normalized to GAPDH.

Results demonstrate a 79% FVII mRNA knock down at 48 hours post dosing after administration of SEQ ID NO pair 179/166. In contrast, the 2′-OH nucleotide bearing siRNA SEQ ID NO pair 180/168 showed no significant knock down (<25%), as shown in Table 5.

TABLE 5 b Results of in vivo knockdown studies Time SEQ ID NO pair 179/166 SEQ ID NO pair 180/168 [hour] Remaining mRNA [%] Remaining mRNA [%] 1 84 92 6 83 88 24 53 100 48 21 76

Example 43 Tissue Distribution of siRNAs Devoid of 2′-OH Residues

The siRNA concentration in the liver tissue samples was determined using a proprietary oligonucleotide detection method as described in WO2010043512. Briefly, the siRNA quantification is based on the hybridization of a fluorescently (Atto-425) labeled PNA-probe (Atto425-OO-GCAAAGGCGTGCCAACT, obtained from Panagene Inc, Korea) complementary to the antisense strand of the siRNA duplex, followed by AEX-HPLC based separation. Quantification was done by fluorescence detection against an external calibration curve that was generated from a dilution series of the two FVII siRNA used in the in vivo experiment (see example 42). For plasma samples between 0.2 to 2 μL and for tissue ˜1 mg aliquots were injected onto the HPLC system.

Liver tissue analysis of the stabilized siRNA lacking 2′-OH nucleotide showed high concentrations of intact antisense strand in the liver in the ug/g range, but ˜95% was present in the 5′-dephosphorylated inactive form (see table IR.04). The resulting RNA with a terminal 2′-OMe nucleotide is not prone for rephosphorylation in the cytoplasm by the phosphokinase hClp1 (see below). In contrast, the antisense strand of the 2′-OH containing siRNA was completely degraded in the tissue within the first 6 hours post dosing.

TABLE 6 Liver tissue analysis of the stabilized siRNA containing no 2′-OH nucleotide SEQ ID NO pair 181/186 SEQ ID NO pair 181/185 Time in Liver [ng/g] in Liver [ng/g] [hour] −5′-Phosphat +5′-Phosphat −5′-Phosphat +5′-Phosphat 1 873 171 9 BDL 6 1351 106  BDL* BDL 24 1043 65 BDL BDL 48 1062 66 BDL BDL *BDL = below detection limit

Example 44 In Vitro Knock Down Activity of siRNAs with Optimized 5′-Ends

An additional in vitro screen for FVII siRNAs was conducted in order to identify siRNAs that may be intracellularly (re-)phosphorylated at the antisense's 5′-end to result in the RNAi-competent species All siRNAs from this screen are shown in Table 7. The alternating 2′-OMe/2′-F modification pattern was identical to the 1^(st) generation design (without any 2′-OH residues) with exception of various modifications at the first two nucleotides at the 5′-end of the antisense strand. The two 5′-terminal nucleotides of the antisense strand were generated as 2′-F or 2′-deoxy modified nucleotides in various combinations with and without an additional 5′-phosphate or 5′-phosphothioate. All siRNAs were screened in dose response (24 nM to 0.00037 nM in 4fold dilutions) for knock down activity after transfection of primary mouse hepatocytes (30000 cells per well; 96 well plate formate) using Lipofectamine 2000 according to the manufacturer's instructions. Two siRNAs were comparable active to the parental duplex (SEQ ID NO pair 182/168); comparable active siRNAs: SEQ ID NO pairs 181/186 and 181/185) in terms of IC₅₀ values, one with a 5′-terminal 2′-F and a phosphate group and one with two 5′-terminal 2′-deoxy nucleotides and a 5′-phosphorothioate (see Table 7 for IC50 values). Both of them are ˜5-6-fold more active compared to the siRNA (SEQ ID NO pair 181/166) used in the first animal experiment with the terminal 2′-OMe nucleotide.

TABLE 7 IC 50 values SEQ SEQ ID ID IC50 NO Sense strand sequence (5′-3′) NO Sense strand sequence (5′-3′) (nM) 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 185 pUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 0.17 182 GcAAAGGcGuGccAAcucAdTsdT 168 UGAGUUGGcACGCCUUUGCdTsdT 0.228 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 189 psdTdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 0.228 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 187 psdTsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 0.554 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 188 pdTsdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 0.631 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 189 pdTsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 0.702 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 190 pusGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 0.749 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 166 puGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 1.002 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 191 psUfGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 1.185 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 192 UfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 2.257 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 193 psUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 2.428 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 194 psdTsdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT 3.208 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 195 usGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 3.974 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 196 uGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 4.235 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 197 dTsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 4.235 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 198 psdTGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 4.704 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 199 dTsdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 5.341 183 (Chol)GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invd 190 pusGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 9.771

Example 45 In Vitro 5′-Phosphorylation of siRNAs with Optimized 5′-Termini

All siRNAs without a 5′-phosphate or 5′-phosphorothioate listed in Table 7 were assessed for phosphorylation by hClp 1 in a HeLa S100 cell extract.

5′-phosphorylation s was analyzed from S100 HeLa extracts as described by Weitzer and Martinez (S. Weitzer and J. Martinez. hClp1: a novel kinase revitalizes RNA metabolism. Cell Cycle 6 (17):2133-2137, 2007). Directly after incubation of 1 μM siRNAs in the S100 HeLa extract containing 5 mM ATP, the solution was analyzed by either IP-RP-HPLC or AEX-HPLC under denaturing conditions by injection of 5 μL sample solution:

-   A. IP-RP-HPLC was done employing a Waters XBridge C₁₈ column (2.5×50     mm, 2.5 μm particle size) at 65° C. column temperature. Gradient     elution was performed using 100 mM hexafluoroisopropanol (HFIP) and     16 mM triethylamine in 1% methanol as eluent A and composition A in     95% methanol as eluent B. A gradient from 1% B to 18% B in 30     minutes was employed. -   B. AEX-HPLC was performed on a Dionex DNA Pac200 column (4×250 mm)     at 50° C. using a 20 mM phosphate buffer containing 10% ACN at     pH=11. Eluent B contained 1 M NaBr in eluent A. A gradient from 25     to 62% B in 18 minutes was employed.

The ratio of 5′-phosphorylation is calculated for each strand of a siRNA from the UV trace at 260 nm using the following equitation (PA is peak area):

%_((5′-phosphorylation))=100*PA_([5′-phosphorylated strand])/(PA_([5′-phosphorylated strand])+PA_([parent strand]))

In Table 8 is shown, that the antisense strand of an siRNA cannot be 5′-phosphorylated, when a 2′-OMe nucleotide is located at the 5′-terminus (SEQ ID NO pair 181/196 and SEQ ID NO pair 181/195). In contrast the antisense strand is susceptible to 5′-phosphorylation, when a 2′-F, 2′-deoxy or 2′-OH nucleotide is incorporated at the 5′-terminus (SEQ ID NO pair 181/195, SEQ ID NO pair 181/192, SEQ ID NO pair 181/197, SEQ ID NO pair 181/199 and SEQ ID NO pair 182/168). The two siRNAs, that were comparably active in the in vitro assay as the parental SEQ ID NO pair 182/168 (SEQ ID NO pair 181/186 and 181/185), are susceptible to 5′-phosphorylation once the synthetically introduced 5′-phosphate/5′-PTO group is cleaved in vivo, eg. by phosphatases.

TABLE 8 Percentage of 5′-phosphorylated strand after 4 hours incubation in S100 HeLa cell extract. Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; Upper case letters A, C, G, U followed by “f” indicates a 2′-fluoro nucleotide.(invdT) represents an inverted deoxythimidine (3′-3′-linked). A phosphorothioate linkages is symbolized with a lower case “s”. dT is deoxythimidine. SEQ sense SEQ antisense ID Sense strand sequence 5′P ID Antisense strand sequence  5′P NO (5′-3′) [%] NO (5′-3′) [%] 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf 52 196 uGfaGfuUfgGfcAfcGfcCfuUfuGfc   0 (invdT) (invdT) 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf 53 195 usGfaGfuUfgGfcAfcGfcCfuUfuGfc   0 (invdT) (invdT) 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf 44 192 UfsGfaGfuUfgGfcAfcGfcCfuUfuGfc  22 (invdT) (invdT) 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf 42 197 dTsGfaGfuUfgGfcAfcGfcCfuUfuGfc  22 (invdT) (invdT) 181 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf 47 199 dTsdGaGfuUfgGfcAfcGfcCfuUfuGf  13 (invdT) c(invdT) 182 GcAAAGGcGuGccAAcucAdTsdT 31 168 UGAGUUGGcACGCCUUUGCdTsd  42 T 184 GfcAfaAfgGfcGfuGfcCfaAfcUfcA 22 168 UGAGUUGGcACGCCUUUGCdTsd 100 T

Example 46 In Vitro DNAse II-Stability of siRNAs with Optimized 5′ Ends

All antisense strands were screened for DNAse II stability as described in example 41. The two antisense strands present in the siRNAs that were comparable active to the parental duplex (SEQ ID NO 186 and SEQ ID NO pair 185 one with a 5′-terminal 2′-F and a phosphate group and one with two 5′-terminal 2′-deoxy nucleotides and a 5′-phosphorthioate are stable towards DNAse II cleavage II (>70% intact strand after 20 hr incubation).

TABLE 9 In vitro stability of siRNAs towards DNase II after 20 hours incubation Sense Antisense % SEQ ID SEQ ID intact NO NO Sequence (5′-3′) strand 181 192 UfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  11 181 197 dTsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)   0 181 199 dTsdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)   0 181 193 psUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 106 181 187 psdTsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  96 181 194 psdTsdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 101 181 191 psUfGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 100 181 198 psdTGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  95 181 186 psdTdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  99 181 185 pUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  71 181 189 pdTsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  74 181 188 pdTsdGaGfuUfgGfcAfcGfcCfuUfuGfc(invdT)  64

Example 47 In Vivo Knock Down Activity of siRNAs with Optimized 5′ Ends

In order to evaluate if the in vitro improvement by optimized 5′-ends transfers to the in vivo situation, we conducted further mouse experiments with GalNAc-palmitoyl conjugates of selected siRNAs (see Table 10). SiRNAs were administered as under identical conditions as described for the first mouse experiment (example 42, this patent application).

For measurement of FVII levels, plasma samples from mice were prepared by collecting blood (9 volumes) by submandibular bleeding into microcentrifuge tubes containing 0.109 mol/L sodium citrate anticoagulant (1 volume) following standard procedures. FVII activity in plasma was measured with a chromogenic method using a BIOPHEN VII kit (Hyphen BioMed/Aniara, Mason, Ohio) following manufacturer's recommendations. Absorbance of colorimetric development was measured using a Tecan Safire2 microplate reader at 405 nm.

The siRNAs under investigation showed improved in vivo activity, fully correlating with the in vitro screening results. FVII activity in serum was reduced by more than 80% for both siRNAs 48 hours post dosing, compared to 49% using the first generation DNase II stable siRNA design (see Table 10). This result clearly underscores the importance of a 5′-terminal nucleotide on the antisense strand that can be effectively phosphorylated, in case phosphatases in vivo cleave the synthetically generated 5′-phosphate or 5′-phosphothioate group. In case of a 5′-terminal 2′-OMe nucleotide as used in the first design or described in the literature as a more potent siRNA design based on in vitro comparison with canonical siRNAs. (Allerson et al. J. Med Chem. 2005, 48, 901-904), the cleavage of the synthetic phosphate in vivo would lead to a strong reduction in potency of the corresponding siRNA.

TABLE 10 In vivo knockdown activity of siRNAs with optimized 5′ends. Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; Upper case letters A, C, G, U followed by “f” indicates a 2′-fluoro nucleotide. Lower case “p” indicates a 5′-phosphate. (invdT) represents an inverted deoxythimidine (3′-3′-linked). A phos- phorothioate linkages is symbolized with a lower case “s”.(NHC6) is the aminohexyl linker incorporated at the 5′-end of the sense strand. GalNAc refers to the structure in formula (IV). % SEQ SEQ remaining ID Sense strand sequence ID Antisense strand sequence FVII in NO (5′-3′) NO (5′-3′) serum 179 GalNAc-(NH2C6)- 166 puGfaGfuUfgGfcAfcGfcCfuUfuGfc 27 GfcAfaAfgGfcGfuGfcCfaAfcUfc (invdT) Af(invdT) 179 GalNAc-(NH2C6)- 190 pusGfaGfuUfgGfcAfcGfcCfuUfuGfc 51 GfcAfaAfgGfcGfuGfcCfaAfcUfc (invdT) Af(invdT) 179 GalNAc-(NH2C6)- 185 pUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc 17 GfcAfaAfgGfcGfuGfcCfaAfcUfc (invdT) Af(invdT) 179 GalNAc-(NH2C6)- 186 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 13 GfcAfaAfgGfcGfuGfcCfaAfcUfc (invdT) Af(invdT)

Example 48 In Vitro Knock Down Activity of siRNAs with Optimized 3′ Ends

To further increase activity of the DNase II stable siRNAs an SAR study of the 3′-overhang was performed. Various combinations of invdT, dTinvdT or dTsdT on either the sense or the antisense strand 3′-overhang were applied to Aha1- and EGFP-targeting siRNAs (see Tables 11 and 12, respectively) and were pairwise compared for composition of both 3′ ends in most potent siRNAs. All siRNAs were screened in dose response (24 nM to 0.00037 nM in 4-fold dilutions) for knock down activity after transfection of primary mouse hepatocytes (30000 cells/well; 96 well plate format) using Lipofectamine 2000 according to the manufacturer's instructions.

TABLE 11 In vitro knock down activity of EGFP-targeting siRNAs with different 3′-ends. SEQ SEQ ID Sense strand sequence ID Antisense strand sequence IC50 NO (5′-3′) NO (5′-3′) (nM  45 GCUGGAGUUCGUGACCGCCdTdT  46 GGCGGUCACGAACUCCAGCdTdT 1.0490 212 GcuGGAGuucGuGAccGccdTsdT 225 GGCGGUcACGAACUCcAGCdTsdT #N/A 201 gcUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 221 dGsGfcGfgUfcAfcGfaAfcUfcCfaGfc(invdT) 0.4377 201 gcUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 214 dGsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.1479 211 gcUfgGfaGfuUfcGfuGfaCfcGfcCfdT(invdT) 223 dGsGfcGfgUfcAfcGfaAfcUfcCfaGfcdT(invdT) 0.5833 203 gcUfgGfaGfuUfcGfuGfaCfcGfcCfdTsdT 214 dGsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.2166 204 GfcUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 224 pGfsGfcGfgUfcAfcGfaAfcUfcCfaGfc(invdT) 0.9100 204 GfcUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 215 pGfsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.2241 207 GfcUfgGfaGfuUfcGfuGfaCfcGfcCfdT(invdT) 218 pGfsGfcGfgUfcAfcGfaAfcUfcCfaGfcdT(invdT) 0.3474 206 GfcUfgGfaGfuUfcGfuGfaCfcGfcCfdTsdT 215 pGfsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.2392 205 GfscUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 220 GfsGfcGfgUfcAfcGfaAfcUfcCfaGfc(invdT) 0.4251 205 GfscUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 216 GfsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.2349 210 GfscUfgGfaGfuUfcGfuGfaCfcGfcCfdT(invdT) 222 GfsGfcGfgUfcAfcGfaAfcUfcCfaGfcdT(invdT) 0.5230 209 GfscUfgGfaGfuUfcGfuGfaCfcGfcCfdTsdT 216 GfsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.4937 200 gscUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 217 pdGsGfcGfgUfcAfcGfaAfcUfcCfaGfc(invdT) 0.2643 200 gscUfgGfaGfuUfcGfuGfaCfcGfcCf(invdT) 213 pdGsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.0936 208 gscUfgGfaGfuUfcGfuGfaCfcGfcCfdT(invdT) 219 pdGsGfcGfgUfcAfcGfaAfcUfcCfaGfcdT(invdT) 0.3776 202 gscUfgGfaGfuUfcGfuGfaCfcGfcCfdTsdT 213 pdGsGfcGfgUfcAfcGfaAfcUfcCfaGfcdTsdT 0.1569

TABLE 12 In vitro knock down activity of Aha1-targeting siRNAs with different 3′-ends. SEQ SEQ ID Sense strand sequence ID Antisense strand sequence IC50 NO (5′-3′) NO (5′-3′) (nM 157 GGAuGAAGuGGAGAuuAGudTsdT 158 ACuAAUCUCcACUUcAUCCdTsdT 0.094 234 GfgAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 246 AfsCfuAfaUfcUfcCfaCfuUfcAfuCfc(invdT) 0.081 234 GfgAfuGfaAfgUfgGfaGfaUfuAfgUf 240 AfsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.036 233 GfgAfuGfaAfgUfgGfaGfaUfuAfgUfdT(invdT) 239 AfsCfuAfaUfcUfcCfaCfuUfcAfuCfcdT(invdT) 0.034 236 GfgAfuGfaAfgUfgGfaGfaUfuAfgUfdTsdT 240 AfsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.040 231 GfsgAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 241 pAfsCfuAfaUfcUfcCfaCfuUfcAfuCfc(invdT) 0.037 231 GfsgAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 267 pAfsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.030 229 GfsgAfuGfaAfgUfgGfaGfaUfuAfgUfdT(invdT) 268 pAfsCfuAfaUfcUfcCfaCfuUfcAfuCfcdT(invdT) 0.024 228 GfsfAfuGfaAfgUfgGfaGfaUfuAfgUfdTsdT 267 pAfsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.021 232 ggAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 245 dAsCfuAfaUfcUfcCfaCfuUfcAfuCfc(invdT) 0.060 232 ggAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 238 dAsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.030 237 ggAfuGfaAfgUfgGfaGfaUfuAfgUfdT(invdT) 244 dAsCfuAfaUfcUfcCfaCfuUfcAfuCfcdT(invdT)  0.045 230 ggAfuGfaAfgUfgGfaGfaUfuAfgUfdTsdT 238 dAsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.025 227 gsgAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 243 pdAsCfuAfaUfcUfcCfaCfuUfcAfuCfc(invdT) 0.045 227 gsgAfuGfaAfgUfgGfaGfaUfuAfgUf(invdT) 266 pdAsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.015 235 gsgAfuGfaAfgUfgGfaGfaUfuAfgUfdT(invdT)  242 pdAsCfuAfaUfcUfcCfaCfuUfcAfuCfcdT(invdT) 0.039 226 gsgAfuGfaAfgUfgGfaGfaUfuAfgUfdTsdT 266 pdAsCfuAfaUfcUfcCfaCfuUfcAfuCfcdTsdT 0.014

It was found, that siRNAs with 2 nucleotide dTsdT-overhangs on the antisense strand performed always better than those with a single invdT overhang at the antisense's 3′-end (while sense strands were the same). Further beneficial was the combination with a sense strand modified with a single invdT-overhang as 3′ overhang.

Example 49 In Vivo Knock Down Activity of siRNAs in Non-Human Primates Preparation of DPCs and Dosing

DPCs were prepared by covalently attaching polymer “149 RAFT” to the indicated siRNA targeting coagulation Factor VII (siF7) at 4:1 wt:wt ratio (polymer:siRNA) through a disulfide linkage and then modifying the polymer-siRNA conjugate with a 2:1 wt:wt mixture of CDM-PEG:CDM-NAG at a 7× wt:wt ratio (CDM:polymer). Cynomolgous monkeys were dosed with 1 mg/kg DPC (polymer weight) and 0.25 mg/kg of the indicated siRNA. One animal received DPC containing siF7 SEQ ID NO pair 151/152, two animals received DPC containing siF7 SEQ ID NO pair 253/254), #1 and #2), and two animals received DPC containing SEQ ID NO pair 251/255, #1 and #2). F7 values were normalized to the average of the two pre-dose values. Animals receiving DPCs containing SEQ ID NO pair 253/254 or SEQ ID NO pair 251/255 had greater levels of F7 knockdown and longer PT than the animal receiving SEQ ID NO pair 251/252.

DPC Injection Procedure

For each injection procedure, animals were given an IM injection containing a combination of ketamine (up to 7 mg/kg) and dexmedetomidine (up to 0.03 mg/kg) and moved to a procedure room. In the procedure room, animals were placed on a water jacketed heating pad and the injection site was shaved and prepped with an antiseptic. An intravenous catheter (20 to 22 gauge) was inserted into a systemic vein (cephalic or small saphenous) and the DPC solution was infused (2 ml/kg) slowly over 1 to 2 minutes. A pulse oximeter was used to monitor the heart rate and oxygen saturation during and immediately following the injection procedure. Each injection procedure took about 20 minutes to perform. After injection the catheter was removed and gentle

pressure was applied to the venipuncture site. Animals were taken back to their cages and given an IM injection of the reversal drug atipamezole (antisedan) (0.10 to 0.15 mg/kg). Animals were monitored until they regained normal activity.

Blood Collection Procedure

Blood samples (1-5 ml) were obtained for the measurement of gene inhibition (F7 activity, coagulation time), blood chemistries, and markers of liver damage (CBC, chemistry panel, ALT, cytokines, complement). For these blood collection procedures, animals were given an IM injection containing a combination of ketamine (up to 7 mg/kg) and dexmedetomidine (up to 0.03 mg/kg). Once sedated, animals were moved on to a portable procedure table and a 22 gauge needle and syringe were used to collect blood from the femoral vein. Immediately after the blood collection, pressure was applied to the venipuncture site and the blood was divided into the appropriate sample tubes for each blood test. Animals were then given an IM injection of the reversal drug atipamezole (antisedan) (0.10 to 0.15 mg/kg) and returned to their cage. No more than 20% of total blood volume was drawn in any 30-day period (estimated blood volume=60 ml/kg). Each blood collection procedure took about 10 minutes to perform.

Factor VII (F7) Activity Measurements

Blood samples from non-human primates were prepared by filling serum separator tubes with whole blood and allowing the blood to clot at room temperature for at least 20 minutes. After clotting, blood tubes were centrifuged for 3 minutes at 9000 rpm, aliquoted into eppendorf tubes, and stored at −20° C. until assayed. F7 activity in serum was measured with a chromogenic method using a BIOPHEN VII kit (Hyphen BioMed/Aniara, Mason, Ohio) following manufacturer's recommendations. Absorbance of colorimetric development was measured using a Tecan Safire2 microplate reader at 405 nm.

Coagulation Tests (Protime, Partial Protime and Fibrinogen)

Blood samples from non-human primates were prepared by completely filling sodium citrate tubes (BD Vacutainer) with whole blood and gently mixing to prevent clot formation. Tubes were transported to a clinical testing lab within one hour and coagulation assays were performed within 4 hours from the time of collection.

TABLE 13 FVII SiRNA used for NHP experiment: Key: lower case letters a, c, g, u, are 2′-O-Methyl nucleotides; Upper case letters A, C, G, U followed by “f” indicates a 2′-fluoro nucleotide. Lower case “p” indicates a 5′-phosphate. (invdT) represents an inverted deoxythimidine (3′-3′-linked). A phosphorothioate linkages is symbolized with a lower case “s”. dT is deoxythimidine. SEQ SEQ ID Sense strand sequence ID Antisense strand sequence NO (5′-3′) NO (5′-3′) 251 (NH2C6)GfuUfgGfuGfaAfuGfgAfgCfuCf 252 pCfsUfgAfgCfuCfcAfuUfcAfcCfaAfc aGf(invdT) (invdT) 253 (NH2C6)GfgUfcCfuGfuUfgUfuGfgUfgAf 254 pAfsUfuCfaCfcAfaCfaAfcAfgGfaCfcd aUf(invdT) TsdT 251 (NH2C6)GfuUfgGfuGfaAfuGfgAfgCfuCf 255 pCfsUfgAfgCfuCfcAfuUfcAfcCfaAfcd aGf(invdT) TsdT

Changing from an single nucleotide (invdT)-3′-overhang on both strands to an asymmetric siRNA design with a 3′-(invdT) overhang on the sense strand and a dTsdT overhang on the antisense strand, but otherwise constant modification pattern lead to a more pronounced serum FVII reduction and a significantly prolonged duration of this effect in non-human primates (see FIG. 6 a). This observation is supported by an expected biologic consequence, namely a more pronounced effect on the prothrombin time corresponding to the extent of Factor 7 reduction (see FIG. 6 b).

Example 50 In Vivo Knock Down Activity of siRNAs with Cleavable RNA Linkers

In Table 14 the in vivo efficacy based on FVII protein inhibition in serum was compared using cholesterol or the GalNAc-palmitoyl siRNA conjugate in the same sequence context in mice. The in vivo experiment was conducted as described in example 42. FVII inhibition was strongly decreased for the cholesterol conjugated siRNAs containing no 2′-OH nucleotide compared to the GalNAc-palmitoyl conjugated counterparts (SEQ ID NO pair 179/166 vs. 179/190, SEQ ID NO pair 257/264 vs. SEQ ID NO pair 179/262, SEQ ID NO pair 257/263 vs. SEQ ID NO pair 179/163 and SEQ ID NO pair 257/166 vs. (SEQ ID NO pair 179/166). In contrast for a 2′-OH containing siRNA the cholesterol conjugate lead to higher FVII inhibition compared to the GalNAc-palmitoyl derivative (SEQ ID NO pair 180/168 vs. SEQ ID NO pair 258/168).

The small molecule ligands GalNAc-palmitoyl and cholesterol used in the described in vivo experiment are connected to the siRNA via a non-cleavable linker to the 5′-end of the sense strand. In case the sense strand exhibit 2′-OH nucleotides the ligand is still cleavable by nucleases (e.g. DNase II in the endosomal or lysosomal compartment). The cleavage reaction releases the free siRNA that is then released into the cytoplasm by the endosomal perturbing activity of the delivery polymer.

For siRNAs lacking a 2′-OH nucleotide in the sense strand, the ligands are stably connected to the duplex, as no enzymatic (nuclease/protease/esterase etc.) or chemical mechanism triggers the cleavage of the ligand. Therefore, fully stable cholesterol conjugated siRNA can be trapped in cell membranes due to the membrane interaction of the lipophilic cholesterol ligand. Even high concentrations of the siRNA in the tissue is not sufficient for effective release of the siRNA into in the cytoplasm. In contrast, the less lipophilic GalNAc-palmitoyl conjugated siRNA can be released into the cytoplasm, due to a less pronounced interaction with cell membranes. For this reason a stable, non-cleavable GalNAc-palmitoyl siRNA conjugate is more efficacious compared to a cholesterol conjugated to the same siRNA.

Developing cleavable linker constructs would help to circumvent the issue of membrane trapping for stably conjugated cholesterol siRNA. Using disulfide linker chemistry is described as an attractive possibility to introduce a defined cleavage site but cleavage is most probably restricted to the reducing environment of specific organelles within the cell (PNAS, 2006, 103, 13872). As cleavage is expected to be slow in the endosomal/lysosomal compartment most of the cholesterol-disulfide conjugated siRNA can still be trapped in membranes as described for the non-cleavable cholesterol conjugates.

TABLE 14 SEQ % FVII SEQ ID ID activity activity Conjugate NO pair NO Sequence 5′->3′ in serum GalNA

179/166 179 GalNAc-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 27 166 puGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 179/190 179 GalNAc-NH2C6-GfcAfaAfgGfcGfuGFcCfaAfcUfcAf(invdT) 51 190 pusGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 179/262 179 GalNAc-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 17 262 pUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 179/263 179 GalNAc-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 13 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 180/168 180 GalNAc-NH2C6-GcAAAGGcGuGccAAcucAdTsdT 86 168 UGAGUUGGcACGCCUUUGCdTsdT Cholesterol 257/166 257 Cholesterol-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 48 166 puGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 257/190 257 Cholesterol-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 93 190 pusGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 257/264 257 Cholesterol-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 63 264 pUfsGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 257/263 257 Cholesterol-NH2C6-GfcAfaAfgGfcGfuGfcCfaAfcUfcAf(invdT) 41 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc(invdT) 258/168 258 Cholesterol-NH2C6-GcAAAGGcGuGccAAcucAdTsdT 50 168 UGAGUUGGcACGCCUUUGCdTsdT

In addition to the well-established disulfide cleavable linker chemistry another possibility is the generation of defined cleavage sites by using 2′-OH nucleotides at certain positions. Introduction of 2′-OH nucleotides at selective positions is a new approach to achieve cleavage of the conjugates from RNA strands. The 2′-OH nucleotides can either be implemented by adding single stranded overhangs with at least one 2′-OH-nucleotide at the 3′- or 5′-end of the RNA strand or by using 2′-OH nucleotides within the duplex region of an siRNA. The enzymatic activity of nucleases present in the endosome/lysosome cleaves selectively at this positions. In a first design the cholesterol was connected to the sense strand via a single stranded overhang containing 3 2′-OH nucleotides (AUC) at the 5′-terminus.

Cholesterol conjugated siRNAs comparing various cleavable linker chemistries are shown in Table 15. All siRNAs have the identical sequence context, just the linker chemistry was altered. Cholesterol was connected to the sense strand via single stranded overhang comprised of a three 2′-OH nucleotides (AUC) to the 5′-terminus. When co-administered with a delivery polymer this siRNA (SEQ ID NO pair 260/263) lead to 77% FVII down modulation in serum in mice, compared to only 60% when using the identical siRNA with a stably attached cholesterol (SEQ ID NO pair 257/263). The same siRNA with a cholesterol conjugated via a linker according to formula Ia to the 5′-terminus of the sense strand (SEQ ID NO pair 261/263) lead to 93% FVII activity reduction in serum. All results were achieved by co-administration of 15 mg/kg of a delivery polymer with 2.5 mg/kg of the cholesterol conjugated siRNA in mice.

TABLE 15 In vivo comparison of various linker chemistries for cholesterol conjugated siRNAs SEQ SEQ % FVII ID Sense strand sequence ID Antisense strand sequence activity NO (5′-3′) NO (5′-3′) in serum 257 Chol-(NH2C6)- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 40 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf (invdT) (invdT) 259 Chol-C6SSC6- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 22 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf (invdT) (invdT) 260 Chol-AUC- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 23 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf (invdT) (invdT) 261 Chol-Cathepsin- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 7 GfcAfaAfgGfcGfuGfcCfaAfcUfcAf (invdT) (invdT)

These results indicate, that the use of a cleavable linker improves the in vivo potency of siRNAs containing no 2′-OH nucleotide. The cleavable linker can either comprised of 2′-OH containing nucleotides, a di-peptide cleavage motive or a disulfide linker chemistry. All cleavable linker constructs improve the in vivo potency in a co-administration setup of a cholesterol conjugated siRNAs with a slow endosomal release delivery polymer.

Example 51 In Vitro Serum Stability of siRNAs with Cleavable Linkers

The stability of the cleavable linker was evaluated in an in vitro stability assay. The cholesterol conjugated sense strands were incubated in 90% mouse serum at 37° C. for various time points. The incubation reaction was stopped by addition of proteinase K in a sodium dodecyl sulfate (SDS) containing buffer-The treatment degrades all proteins and enzymes without interfering with the RNA strand integrity. 25 μL of this solution was directly injected onto a AEX-HPLC system connected to a UV detector at 260 nm. AEX-HPLC was performed on a Dionex DNA Pac200 column (4×250 mm) at 75° C. using a 20 mM Tris buffer containing 50% ACN at pH=8. 800 mM NaBr in eluent B serves as eluent salt. A gradient from 25 to 62% B in 18 minutes was employed.

The cholesterol containing single stranded RNA elutes from the HPLC column as a broad peak at 260 nm After cleavage of the cholesterol sharp symmetric peaks is observed at lower retention time. Cleavage rate of cholesterol was determined by the following equitation (PA=Peak Area):

%_((free RNA))=100*PA_([free RNA])/(PA_([free RNA])+PA_([cholesterol conjugated RNA]))

In vitro it was shown, that the 3 nt nucleotide (AUC)-overhang is quantitatively cleaved in less than 1 hour in 90% mouse serum. The cleavage occurs 3′ to the two pyrimidine nucleotides in the overhang, leading to two distinct cleavage metabolites (peak areas of metabolites were summarized for data evaluation). In contrast, the di-peptide containing linker according to formula Ia, the disulfide and the stably linked cholesterol are fully stable in mouse serum.

Example 52 Tissue Distribution of siRNAs with Cleavable Linkers

The siRNA concentration in the liver tissue samples was determined using a proprietary oligonucleotide detection method as described in WO2010043512. Briefly, the siRNA quantification is based on the hybridization of a fluorescently (Atto-425) labeled PNA-probe (Atto425-OO-TGAGTTGGCACGCCTTT obtained from Panagene Inc, Korea) complementary to the sense strand of the siRNA duplex, followed by AEX-HPLC based separation. Quantification was done by fluorescence detection against an external calibration curve that was generated from a dilution series of the two FVII siRNA used in the in vivo experiment (see example 42). For plasma samples between 0.2 to 2 μL and for tissue ˜1 mg aliquots were injected onto the HPLC system.

In Table 16 results from liver tissue analysis are shown. When analyzing the siRNA content it was found, that the sense strand that is present in liver tissue, is quantitatively cleaved from cholesterol when using either the di-peptide linker motive or the 3 nt 5′-overhang with the unmodified linker sequence AUC. In contrast, only 15% of the disulfide linked siRNA that is present in the liver is cleaved from cholesterol within the first 48 hours post dosing and nothing of the stably attached cholesterol is cleaved from the siRNA.

When comparing the absolute amounts of cholesterol-free siRNA in liver tissue similar amounts were found for the disulfide linker and for the RNA AUC-linker, nicely correlating with equal FVII serum activity 48 hours post dosing The lower FVII activity achieved with the di-peptide linked cholesterol siRNA fully correlates with the higher absolute amount of the cleaved cholesterol-free siRNA.

The total amount of cholesterol siRNA conjugate equipped with an (AUC)-linker on the sense strand delivered into the liver is ˜6-fold lower as compared to the stably or the disulfide attached cholesterol and ˜3-fold lower compared to the di-peptide conjugated cholesterol siRNA. The reduced tissue presence can be attributed to the fact that the AUC-linker is not only a substrate for intracellular nucleases, but also for nucleases present in circulation as shown in the in vitro incubation with mouse serum. When the cholesterol ligand is cleaved from the siRNA already in circulation the resulting siRNA is prone to renal clearance is rapidly excreted into urine without delivery into tissue.

TABLE 16 Total % sense siRNA cleaved SEQ SEQ in ligand ID Sense strand sequence ID Antisense strand sequence Liver in NO (5′-3′) NO (5′-3′) [ng/g] liver 257 Chol-(NH2C6)- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 5837 0 GfcAfaAfgGfcGfuGfcCfaAfeUf (invdT) cAf(invdT) 259 Chol-C6SSC6- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 4357 14.8 GfcAfaAfgGfcGfuGfcCfaAfcUf (invdT) cAf(invdT) 260 Chol-AUC- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc  912 96.1 GfcAfaAfgGfcGfuGfcCfaAfcUf (invdT) cAf(invdT) 261 Chol-Cathepsin- 263 psdTdGfaGfuUfgGfcAfcGfcCfuUfuGfc 2760 99.8 GfcAfaAfgGfcGfuGfcCfaAfcUf (invdT) cAf(invdT) In the following tables siRNAs used in the examples are summarized:

TABLE 17 Core sequences SEQ SEQ ID Sense strand ID Antisense strand NO sequence (5′-3′) NO sequence (5′-3′)   1 ACAUGAAGCAGCACGACUU   2 AAGUCGUGCUGCUUCAUGU   3 GCCCGACAACCACUACCUG   4 CAGGUAGUGGUUGUCGGGC   5 CGAGAAGCGCGAUCACAUG   6 CAUGUGAUCGCGCUUCUCG   7 AUAUCAUGGCCGACAAGCA   8 UGCUUGUCGGCCAUGAUAU   9 ACAAGCUGGAGUACAACUA  10 UAGUUGUACUCCAGCUUGU  11 GCAGCUCGCCGACCACUAC  12 GUAGUGGUCGGCGAGCUGC  13 CGUCCAGGAGCGCACCAUC  14 GAUGGUGCGCUCCUGGACG  15 GCUGGAGUUCGUGACCGCC  16 GGCGGUCACGAACUCCAGC  17 CCACCCUGACCUACGGCGU  18 ACGCCGUAGGUCAGGGUGG  19 CGACUUCAAGGAGGACGGC  20 GCCGUCCUCCUUGAAGUCG  21 UUCAAGAUCCGCCACAACA  22 UGUUGUGGCGGAUCUUGAA  23 GGCAACUACAAGACCCGCG  24 CGCGGGUCUUGUAGUUGCC  25 CCGGCAAGCUGCCCGUGCC  26 GGCACGGGCAGCUUGCCGG  27 UGCCCAUCCUGGUCGAGCU  28 AGCUCGACCAGGAUGGGCA  29 CAAGUUCAGCGUGUCCGGC  30 GCCGGACACGCUGAACUUG 151 GGAAUCUUAUAUUUGAUCCAA 152 UUGGAUCAAAUAUAAGAUUCCCU 155 GGAUGAAGUGGAGAUUAGU 156 ACUAAUCUCCACUUCAUCC 161 GCAAAGGCGUGCCAACUCA 162 UGAGUUGGCACGCCUUUGC 161 GCAAAGGCGUGCCAACUCA 178 TGAGUUGGCACGCCUUUGC 161 GCAAAGGCGUGCCAACUCA 256 TGAGUUGGCACGCCUUUGC 163 GGAUCAUCUCAAGUCUUAC 164 GUAAGACUUGAGAUGAUCC 171 UGACCACAGUCGGAUUAAA 172 UUUAAUCCGACUGUGGUCA 247 GUUGGUGAAUGGAGCUCAG 248 CUGAGCUCCAUUCACCAAC 249 GGUCCUGUUGUUGGUGAAU 250 AUUCACCAACAACAGGACC

TABLE 18 Mapping of core sequences and modified sequence Core sequences Sense Antisense Modified sequences SEQ strand SEQ strand SEQ SEQ ID sequence  ID sequence ID Sense strand ID Antisense strand NO (5′-3′) NO (5′-3′) NO sequence (5′-3′) NO sequence (5′-3′)   1 ACAUGAAGC   2 AAGUCGUGC  31 ACAUGAAGCAG  32 AAGUCGUGCUGCU AGCACGACU UGCUUCAUG CACGACUUdTdT UCAUGUdTdT U U   1 ACAUGAAGC   2 AAGUCGUGC  61 AfcAfuGfaAfgCfa  62 paAfgUfcGfuGfcUfg AGCACGACU UGCUUCAUG GfcAfcGfaCfuUfd CfuUfcAfuGfudTsdT U U TsdT   1 ACAUGAAGC   2 AAGUCGUGC  91 dAcdAudGadAgdC  92 padAgdTcdGudGcdTg AGCACGACU UGCUUCAUG adGcdAcdGadCud dCudTcdAudGudTsd U U TdTsdT T   1 ACAUGAAGC   2 AAGUCGUGC 121 AfdCAfdTGfdAAf 122 pdAAfdGUfdCGfdTG AGCACGACU UGCUUCAUG dGCfdAGfdCAfdC fdCUfdGCfdTUfdCAf U U GfdACfdTUfdTsdT dTGfdTdTsdT   3 GCCCGACAA   4 CAGGUAGUG  33 GCCCGACAACC  34 CAGGUAGUGGUU CCACUACCU GUUGUCGGG ACUACCUGdTdT GUCGGGCdTdT G C   3 GCCCGACAA   4 CAGGUAGUG  63 GfcCfcGfaCfaAfcC  64 pcAfgGfuAfgUfgGfu CCACUACCU GUUGUCGGG faCfuAfcCfuGfdTs UfgUfcGfgGfcdTsdT G C dT   3 GCCCGACAA   4 CAGGUAGUG  93 dGcdCcdGadCadA  94 pcdAgdGudAgdTgdG CCACUACCU GUUGUCGGG cdCadCudAcdCud udTgdTcdGgdGcdTsd G C GdTsdT T   3 GCCCGACAA   4 CAGGUAGUG 123 GfdCCfdCGfdACf 124 pdCAfdGGfdTAfdGU CCACUACCU GUUGUCGGG dAAfdCCfdACfdT fdGGfdTUfdGUfdCG G C AfdCCfdTGfdTsdT fdGGfdCdTsdT   5 CGAGAAGCG   6 CAUGUGAUC  35 CGAGAAGCGCG  36 CAUGUGAUCGCGC CGAUCACAU GCGCUUCUC AUCACAUGdTdT UUCUCGdTdT G G   5 CGAGAAGCG   6 CAUGUGAUC  65 CfgAfgAfaGfcGfc  66 pcAfuGfuGfaUfcGfc CGAUCACAU GCGCUUCUC GfaUfcAfcAfuGfd GfcUfuCfuCfgdTsdT G G TsdT   5 CGAGAAGCG   6 CAUGUGAUC  95 dCgdAgdAadGcdG  96 pcdAudGudGadTcdG CGAUCACAU GCGCUUCUC cdGadTcdAcdAud cdGcdTudCudCgdTsd G G GdTsdT T   5 CGAGAAGCG   6 CAUGUGAUC 125 CfdGAfdGAfdAGf 126 pdCAfdTGfdTGfdAU CGAUCACAU GCGCUUCUC dCGfdCGfdAUfdC fdCGfdCGfdCUfdTCf G G AfdCAfdTGfdTsdT dTCfdGdTsdT   7 AUAUCAUGG   8 UGCUUGUCG  37 AUAUCAUGGCC  38 UGCUUGUCGGCCA CCGACAAGC GCCAUGAUA GACAAGCAdTdT UGAUAUdTdT A U   7 AUAUCAUGG   8 UGCUUGUCG  67 AfuAfuCfaUfgGfc  68 puGfcUfuGfuCfgGfc CCGACAAGC GCCAUGAUA CfgAfcAfaGfcAfd CfaUfgAfuAfudTsdT A U TsdT   7 AUAUCAUGG   8 UGCUUGUCG  97 dAudAudCadTgdG  98 pudGcdTudGudCgdG CCGACAAGC GCCAUGAUA cdCgdAcdAadGcd cdCadTgdAudAudTsd A U AdTsdT T   7 AUAUCAUGG   8 UGCUUGUCG 127 AfdTAfdTCfdAUf 128 pdTGfdCUfdTGfdTCf CCGACAAGC GCCAUGAUA dGGfdCCfdGAfdC dGGfdCCfdAUfdGAf A U AfdAGfdCAfdTsd dTAfdTdTsdT T   9 ACAAGCUGG  10 UAGUUGUAC  39 ACAAGCUGGAG  40 UAGUUGUACUCCA AGUACAACU UCCAGCUUG UACAACUAdTdT GCUUGUdTdT A U   9 ACAAGCUGG  10 UAGUUGUAC  69 AfcAfaGfcUfgGfa  70 puAfgUfuGfuAfcUfc AGUACAACU UCCAGCUUG GfuAfcAfaCfuAfd CfaGfcUfuGfudTsdT A U TsdT   9 ACAAGCUGG  10 UAGUUGUAC  99 dAcdAadGcdTgdG 100 pudAgdTudGudAcdT AGUACAACU UCCAGCUUG adGudAcdAadCud cdCadGcdTudGudTsd A U AdTsdT T   9 ACAAGCUGG  10 UAGUUGUAC 129 AfdCAfdAGfdCUf 130 pdTAfdGUfdTGfdTA AGUACAACU UCCAGCUUG dGGfdAGfdTAfdC fdCUfdCCfdAGfdCUf A U AfdACfdTAfdTsdT dTGfdTdTsdT  11 GCAGCUCGC  12 GUAGUGGUC  41 GCAGCUCGCCG  42 GUAGUGGUCGGC CGACCACUA GGCGAGCUG ACCACUACdTdT GAGCUGCdTdT C C  11 GCAGCUCGC  12 GUAGUGGUC  71 GfcAfgCfuCfgCfc  27 pgUfaGfuGfgUfcGfg CGACCACUA GGCGAGCUG GfaCfcAfcUfaCfdT CfgAfgCfuGfcdTsdT C C sdT  11 GCAGCUCGC  12 GUAGUGGUC 101 dGcdAgdCudCgdC 102 pgdTadGudGgdTcdG CGACCACUA GGCGAGCUG cdGadCcdAcdTad gdCgdAgdCudGcdTsd C C CdTsdT T  11 GCAGCUCGC  12 GUAGUGGUC 131 GfdCAfdGCfdTCf 132 pdGUfdAGfdTGfdGU CGACCACUA GGCGAGCUG dGCfdCGfdACfdC fdCGfdGCfdGAfdGC C C AfdCUfdACfdTsd fdTGfdCdTsdT T  13 CGUCCAGGA  14 GAUGGUGCG  43 CGUCCAGGAGC  44 GAUGGUGCGCUCC GCGCACCAU CUCCUGGAC GCACCAUCdTdT UGGACGdTdT C G  13 CGUCCAGGA  14 GAUGGUGCG  73 CfgUfcCfaGfgAfg  74 pgAfuGfgUfgCfgCfu GCGCACCAU CUCCUGGAC CfgCfaCfcAfuCfdT CfcUfgGfaCfgdTsdT C G sdT  13 CGUCCAGGA  14 GAUGGUGCG 103 dCgdTcdCadGgdA 104 pgdAudGgdTgdCgdC GCGCACCAU CUCCUGGAC gdCgdCadCcdAud udCcdTgdGadCgdTsd C G CdTsdT T  13 CGUCCAGGA  14 GAUGGUGCG 133 CfdGUfdCCfdAGf 134 pdGAfdTGfdGUfdGC GCGCACCAU CUCCUGGAC dGAfdGCfdGCfdA fdGCfdTCfdCUfdGGf C G CfdCAfdTCfdTsdT dACfdGdTsdT  15 GCUGGAGUU  16 GGCGGUCAC  45 GCUGGAGUUCG  46 GGCGGUCACGAAC CGUGACCGC GAACUCCAG UGACCGCCdTdT UCCAGCdTdT C C  15 GCUGGAGUU  16 GGCGGUCAC  75 GfcUfgGfaGfuUfc  76 pgGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd AfcUfcCfaGfcdTsdT C C TsdT  15 GCUGGAGUU  16 GGCGGUCAC 105 dGcdTgdGadGudT 106 pgdGcdGgdTcdAcdG CGUGACCGC GAACUCCAG cdGudGadCcdGcd adAcdTcdCadGcdTsd C C CdTsdT T  15 GCUGGAGUU  16 GGCGGUCAC 135 GfdCUfdGGfdAGf 136 pdGGfdCGfdGUfdCA CGUGACCGC GAACUCCAG dTUfdCGfdTGfdA fdCGfdAAfdCUfdCCf C C CfdCGfdCCfdTsdT dAGfdCdTsdT  15 GCUGGAGUU  16 GGCGGUCAC 200 gscUfgGfaGfuUfc 213 pdGsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCf aAfcUfcCfaGfcdTsdT C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 201 gcUfgGfaGfuUfcG 214 dGsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG fuGfaCfcGfcCf AfcUfcCfaGfcdTsdT C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 202 gscUfgGfaGfuUfc 213 pdGsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd aAfcUfcCfaGfcdTsdT C C TsdT  15 GCUGGAGUU  16 GGCGGUCAC 203 gcUfgGfaGfuUfcG 214 dGsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG fuGfaCfcGfcCfdTs AfcUfcCfaGfcdTsdT C C dT  15 GCUGGAGUU  16 GGCGGUCAC 204 GfcUfgGfaGfuUfc 215 pGfsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCf aAfcUfcCfaGfcdTsdT C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 205 GfscUfgGfaGfuUfc 216 GfsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG GfuGfaCfcGfcCf AfcUfcCfaGfcdTsdT C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 206 GfcUfgGfaGfuUfc 215 pGfsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd aAfcUfcCfaGfcdTsdT C C TsdT  15 GCUGGAGUU  16 GGCGGUCAC 200 gscUfgGfaGfuUfc 217 pdGsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCf aAfcUfcCfaGfc(invdT) C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 207 GfcUfgGfaGfuUfc 218 pGfsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd aAfcUfcCfaGfcdT C C T(invdT) (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 208 gscUfgGfaGfuUfc 219 pdGsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd aAfcUfcCfaGfcdT C C T(invdT) (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 205 GfscUfgGfaGfuUfc 220 GfsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG GfuGfaCfcGfcCf AfcUfcCfaGfc(invdT) C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 201 gcUfgGfaGfuUfcG 221 dGsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG fuGfaCfcGfcCf AfcUfcCfaGfc(invdT) C C (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 209 GfscUfgGfaGfuUfc 216 GfsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd AfcUfcCfaGfcdTsdT C C TsdT  15 GCUGGAGUU  16 GGCGGUCAC 210 GfscUfgGfaGfuUfc 222 GfsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG GfuGfaCfcGfcCfd AfcUfcCfaGfcdT C C T(invdT) (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 211 gcUfgGfaGfuUfcG 223 dGsGfcGfgUfcAfcGfa CGUGACCGC GAACUCCAG fuGfaCfcGfcCfdT AfcUfcCfaGfcdT C C (invdT) (invdT)  15 GCUGGAGUU  16 GGCGGUCAC 204 GfcUfgGfaGfuUfc 224 pGfsGfcGfgUfcAfcGf CGUGACCGC GAACUCCAG GfuGfaCfcGfcCf aAfcUfcCfaGfc C C (invdT) (invdT)  15 GCUGGAGUU  16 GGCGGUCAC  45 GCUGGAGUUCG  46 GGCGGUCACGAAC CGUGACCGC GAACUCCAG UGACCGCCdTdT UCCAGCdTdT C C  15 GCUGGAGUU  16 GGCGGUCAC 212 GcuGGAGuucGuG 225 GGCGGUcACGAAC CGUGACCGC GAACUCCAG AccGccdTsdT UCcAGCdTsdT C C  17 CCACCCUGA  18 ACGCCGUAG  47 CCACCCUGACC  48 ACGCCGUAGGUCA CCUACGGCG GUCAGGGUG UACGGCGUdTdT GGGUGGdTdT U G  17 CCACCCUGA  18 ACGCCGUAG  77 CfcAfcCfcUfgAfc  78 paCfgCfcGfuAfgGfuC CCUACGGCG GUCAGGGUG CfuAfcGfgCfgUfd faGfgGfuGfgdTsdT U G TsdT  17 CCACCCUGA  18 ACGCCGUAG 107 dCcdAcdCcdTgdA 108 padCgdCcdGudAgdG CCUACGGCG GUCAGGGUG cdCudAcdGgdCgd udCadGgdGudGgdTs U G TdTsdT dT  17 CCACCCUGA  18 ACGCCGUAG 137 CfdCAfdCCfdCUf 138 pdACfdGCfdCGfdTA CCUACGGCG GUCAGGGUG dGAfdCCfdTAfdC fdGGfdTCfdAGfdGG U G GfdGCfdGUfdTsd fdTGfdGdTsdT T  19 CGACUUCAA  20 GCCGUCCUCC  49 CGACUUCAAGG  50 GCCGUCCUCCUUG GGAGGACGG UUGAAGUCG AGGACGGCdTdT AAGUCGdTdT C  19 CGACUUCAA  20 GCCGUCCUCC  79 CfgAfcUfuCfaAfg  80 pgCfcGfuCfcUfcCfuU GGAGGACGG UUGAAGUCG GfaGfgAfcGfgCfd fgAfaGfuCfgdTsdT C TsdT  19 CGACUUCAA  20 GCCGUCCUCC 109 dCgdAcdTudCadA 110 pgdCcdGudCcdTcdCu GGAGGACGG UUGAAGUCG gdGadGgdAcdGgd dTgdAadGudCgdTsd C CdTsdT T  19 CGACUUCAA  20 GCCGUCCUCC 139 CfdGAfdCUfdTCf 140 pdGCfdCGfdTCfdCU GGAGGACGG UUGAAGUCG dAAfdGGfdAGfdG fdCCfdTUfdGAfdAGf C AfdCGfdGCfdTsd dTCfdGdTsdT T  21 UUCAAGAUC  22 UGUUGUGGC  51 UUCAAGAUCCG  52 UGUUGUGGCGGA CGCCACAAC GGAUCUUGA CCACAACAdTdT UCUUGAAdTdT A A  21 UUCAAGAUC  22 UGUUGUGGC  81 UfuCfaAfgAfuCfc  82 puGfuUfgUfgGfcGfg CGCCACAAC GGAUCUUGA GfcCfaCfaAfcAfdT AfuCfuUfgAfadTsdT A A sdT  21 UUCAAGAUC  22 UGUUGUGGC 111 dTudCadAgdAudC 112 pudGudTgdTgdGcdG CGCCACAAC GGAUCUUGA cdGcdCadCadAcd gdAudCudTgdAadTsd A A AdTsdT T  21 UUCAAGAUC  22 UGUUGUGGC 141 UfdTCfdAAfdGAf 142 pdTGfdTUfdGUfdGG CGCCACAAC GGAUCUUGA dTCfdCGfdCCfdA fdCGfdGAfdTCfdTUf A A CfdAAfdCAfdTsd dGAfdAdTsdT T  23 GGCAACUAC  24 CGCGGGUCU  53 GGCAACUACAA  54 CGCGGGUCUUGUA AAGACCCGC UGUAGUUGC GACCCGCGdTdT GUUGCCdTdT G C  23 GGCAACUAC  24 CGCGGGUCU  83 GfgCfaAfcUfaCfa  84 pcGfcGfgGfuCfuUfg AAGACCCGC UGUAGUUGC AfgAfcCfcGfcGfd UfaGfuUfgCfcdTsdT G C TsdT  23 GGCAACUAC  24 CGCGGGUCU 113 dGgdCadAcdTadC 114 pcdGcdGgdGudCudT AAGACCCGC UGUAGUUGC adAgdAcdCcdGcd gdTadGudTgdCcdTsd G C GdTsdT T  23 GGCAACUAC  24 CGCGGGUCU 143 GfdGCfdAAfdCUf 144 pdCGfdCGfdGGfdTC AAGACCCGC UGUAGUUGC dACfdAAfdGAfdC fdTUfdGUfdAGfdTUf G C CfdCGfdCGfdTsdT dGCfdCdTsdT  25 CCGGCAAGC  26 GGCACGGGC  55 CCGGCAAGCUG  56 GGCACGGGCAGCU UGCCCGUGC AGCUUGCCG CCCGUGCCdTdT UGCCGGdTdT C G  25 CCGGCAAGC  26 GGCACGGGC  85 CfcGfgCfaAfgCfu  86 pgGfcAfcGfgGfcAfg UGCCCGUGC AGCUUGCCG GfcCfcGfuGfcCfd CfuUfgCfcGfgdTsdT C G TsdT  25 CCGGCAAGC  26 GGCACGGGC 115 dCcdGgdCadAgdC 116 pgdGcdAcdGgdGcdA UGCCCGUGC AGCUUGCCG udGcdCcdGudGcd gdCudTgdCcdGgdTsd C G CdTsdT T  25 CCGGCAAGC  26 GGCACGGGC 145 CfdCGfdGCfdAAf 146 pdGGfdCAfdCGfdGG UGCCCGUGC AGCUUGCCG dGCfdTGfdCCfdC fdCAfdGCfdTUfdGCf C G GfdTGfdCCfdTsdT dCGfdGdTsdT  27 UGCCCAUCC  28 AGCUCGACC  57 UGCCCAUCCUG  58 AGCUCGACCAGGA UGGUCGAGC AGGAUGGGC GUCGAGCUdTdT UGGGCAdTdT U A  27 UGCCCAUCC  28 AGCUCGACC  87 UfgCfcCfaUfcCfu  88 paGfcUfcGfaCfcAfgG UGGUCGAGC AGGAUGGGC GfgUfcGfaGfcUfd faUfgGfgCfadTsdT U A TsdT  27 UGCCCAUCC  28 AGCUCGACC 117 dTgdCcdCadTcdCu 118 padGcdTcdGadCcdAg UGGUCGAGC AGGAUGGGC dGgdTcdGadGcdT dGadTgdGgdCadTsdT U A dTsdT  27 UGCCCAUCC  28 AGCUCGACC 147 UfdGCfdCCfdAUf 148 pdAGfdCUfdCGfdAC UGGUCGAGC AGGAUGGGC dCCfdTGfdGUfdC fdCAfdGGfdAUfdGG U A GfdAGfdCUfdTsd fdGCfdAdTsdT T  29 CAAGUUCAG  30 GCCGGACAC  59 CAAGUUCAGCG  60 GCCGGACACGCUG CGUGUCCGG GCUGAACUU UGUCCGGCdTdT AACUUGdTdT C G  29 CAAGUUCAG  30 GCCGGACAC  89 CfaAfgUfuCfaGfc  90 pgCfcGfgAfcAfcGfcU CGUGUCCGG GCUGAACUU GfuGfuCfcGfgCfd fgAfaCfuUfgdTsdT C G TsdT  29 CAAGUUCAG  30 GCCGGACAC 119 dCadAgdTudCadG 120 pgdCcdGgdAcdAcdG CGUGUCCGG GCUGAACUU cdGudGudCcdGgd cdTgdAadCudTgdTsd C G CdTsdT T  29 CAAGUUCAG  30 GCCGGACAC 149 CfdAAfdGUfdTCf 150 pdGCfdCGfdGAfdCA CGUGUCCGG GCUGAACUU dAGfdCGfdTGfdT fdCGfdCUfdGAfdAC C G CfdCGfdGCfdTsdT fdTUfdGdTsdT 151 GGAAUCUUA 152 UUGGAUCAA 153 GGAAUCuuAuAu 154 uuGGAUcAAAuAuA UAUUUGAUC AUAUAAGAU uuGAUCcAsA AGAuUCcscsU CAA UCCCU 151 GGAAUCUUA 152 UUGGAUCAA 265 (Chol)GGAAUCuu 154 uuGGAUcAAAuAuA UAUUUGAUC AUAUAAGAU AuAuuuGAUCcAs AGAuUCcscsU CAA UCCCU A 155 GGAUGAAGU 156 ACUAAUCUC 157 GGAuGAAGuGG 158 ACuAAUCUCcACU GGAGAUUAG CACUUCAUC AGAuuAGudTsdT UcAUCCdTsdT U C 155 GGAUGAAGU 156 ACUAAUCUC 160 (NH2C6)GfgAfuGf 159 pasCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC aAfgUfgGfaGfaUf CfuUfcAfuCfc(invdT) U C uAfgUf(invdT) 155 GGAUGAAGU 156 ACUAAUCUC 226 gsgAfuGfaAfgUfg 266 pdAsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUfd aCfuUfcAfuCfcdTsdT U C TsdT 155 GGAUGAAGU 156 ACUAAUCUC 227 gsgAfuGfaAfgUfg 266 pdAsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUf aCfuUfcAfuCfcdTsdT U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 228 GfsgAfuGfaAfgUf 267 pAfsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC gGfaGfaUfuAfgUf aCfuUfcAfuCfcdTsdT U C dTsdT 155 GGAUGAAGU 156 ACUAAUCUC 229 GfsgAfuGfaAfgUf 268 pAfsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC gGfaGfaUfuAfgUf aCfuUfcAfuCfcdT U C dT(invdT) (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 230 ggAfuGfaAfgUfgG 238 dAsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC faGfaUfuAfgUfdTs CfuUfcAfuCfcdTsdT U C dT 155 GGAUGAAGU 156 ACUAAUCUC 231 GfsgAfuGfaAfgUf 267 pAfsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC gGfaGfaUfuAfgUf aCfuUfcAfuCfcdTsdT U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 232 ggAfuGfaAfgUfgG 238 dAsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC faGfaUfuAfgUf CfuUfcAfuCfcdTsdT U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 233 GfgAfuGfaAfgUfg 239 AfsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUfd CfuUfcAfuCfcdT U C T(invdT) (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 234 GfgAfuGfaAfgUfg 240 AfsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUf CfuUfcAfuCfcdTsdT U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 231 GfsgAfuGfaAfgUf 241 pAfsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC gGfaGfaUfuAfgUf aCfuUfcAfuCfc U C (invdT) (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 234 GfgAfuGfaAfgUfg 159 pasCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUf CfuUfcAfuCfc(invdT) U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 235 gsgAfuGfaAfgUfg 242 pdAsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUfd aCfuUfcAfuCfcdT U C T(invdT) (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 236 GfgAfuGfaAfgUfg 240 AfsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUfd CfuUfcAfuCfcdTsdT U C TsdT 155 GGAUGAAGU 156 ACUAAUCUC 227 gsgAfuGfaAfgUfg 243 pdAsCfuAfaUfcUfcCf GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUf aCfuUfcAfuCfc U C (invdT) (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 237 ggAfuGfaAfgUfgG 244 dAsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC faGfaUfuAfgUfdT CfuUfcAfuCfcdT U C (invdT) (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 232 ggAfuGfaAfgUfgG 245 dAsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC faGfaUfuAfgUf CfuUfcAfuCfc(invdT) U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 234 GfgAfuGfaAfgUfg 246 AfsCfuAfaUfcUfcCfa GGAGAUUAG CACUUCAUC GfaGfaUfuAfgUf CfuUfcAfuCfc(invdT) U C (invdT) 155 GGAUGAAGU 156 ACUAAUCUC 157 GGAuGAAGuGG 158 ACuAAUCUCcACU GGAGAUUAG CACUUCAUC AGAuuAGudTsdT UcAUCCdTsdT U C 161 GCAAAGGCG 162 UGAGUUGGC 165 (NH2C6)GfcAfaAf 166 puGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG gGfcGfuGfcCfaAfc GfcCfuUfuGfc(invdT) A C UfcAf(invdT) 161 GCAAAGGCG 162 UGAGUUGGC 167 (NH2C6)GcAAAG 168 UGAGUUGGcACGC UGCCAACUC ACGCCUUUG GcGuGccAAcucAd CUUUGCdTsdT A C TsdT 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 166 puGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 180 GalNAc-(NH2C6)- 168 UGAGUUGGcACGC UGCCAACUC ACGCCUUUG GcAAAGGcGuGcc CUUUGCdTsdT A C AAcucAdTsdT 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 185 pUfsGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 186 psdTdGaGfuUfgGfcA UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf fcGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 187 psdTsGfaGfuUfgGfcA UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf fcGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 188 pdTsdGaGfuUfgGfcA UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf fcGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 189 pdTsGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 190 pusGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf GfcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 166 puGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf GfcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 191 psUfGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 192 UfsGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf GfcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 193 psUfsGfaGfuUfgGfcA UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf fcGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 194 psdTsdGaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf AfcGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 195 usGfaGfuUfgGfcAfcG UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf fcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 196 uGfaGfuUfgGfcAfcGf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 197 dTsGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf GfcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 198 psdTGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 199 dTsdGaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 183 (Chol)GfcAfaAfgG 190 pusGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG fcGfuGfcCfaAfcUf GfcCfuUfuGfc(invdT) A C cAf(invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 196 uGfaGfuUfgGfcAfcGf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 195 usGfaGfuUfgGfcAfcG UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf fcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 181 GfcAfaAfgGfcGfu 192 UfsGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf GfcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 197 dTsGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf GfcCfuUfuGfc(invdT) A C (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 181 GfcAfaAfgGfcGfu 199 dTsdGaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcCfaAfcUfcAf cGfcCfuUfuGfc A C (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 182 GcAAAGGcGuGcc 168 UGAGUUGGcACGC UGCCAACUC ACGCCUUUG AAcucAdTsdT CUUUGCdTsdT A C 161 GCAAAGGCG 162 UGAGUUGGC 184 GfcAfaAfgGfcGfu 168 UGAGUUGGcACGC UGCCAACUC ACGCCUUUG GfcCfaAfcUfcA CUUUGCdTsdT A C 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 166 puGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 190 pusGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 185 pUfsGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu cGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 178 TGAGUUGGC 179 GalNAc-(NH2C6)- 186 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 166 puGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 190 pusGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 179 GalNAc-(NH2C6)- 262 pUfsGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu cGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 179 GalNAc-(NH2C6)- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu A C GfcCfaAfcUfcAf AfcGfcCfuUfuGfc (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 257 Chol-(NH2C6)- 166 puGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 257 Chol-(NH2C6)- 190 pusGfaGfuUfgGfcAfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu GfcCfuUfuGfc(invdT) A C GfcCfaAfcUfcAf (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 257 Chol-(NH2C6)- 264 pUfsGfaGfuUfgGfcAf UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu cGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 257 Chol-(NH2C6)- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 162 UGAGUUGGC 258 Chol-(NH2C6)- 168 UGAGUUGGcACGC UGCCAACUC ACGCCUUUG GcAAAGGcGuGcc CUUUGCdTsdT A C AAcucAdTsdT 161 GCAAAGGCG 256 TGAGUUGGC 257 Chol-(NH2C6)- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 259 Chol-C6SSC6- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 260 Chol-AUC- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 261 Chol-Cathepsin- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 257 Chol-(NH2C6)- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 259 Chol-C6SSC6- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 260 Chol-AUC- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 161 GCAAAGGCG 256 TGAGUUGGC 261 Chol-Cathepsin- 263 psdTdGfaGfuUfgGfc UGCCAACUC ACGCCUUUG GfcAfaAfgGfcGfu AfcGfcCfuUfuGfc A C GfcCfaAfcUfcAf (invdT) (invdT) 163 GGAUCAUCU 164 GUAAGACUU 169 (NH2C6)GGAUfCf 170 GUfAAGACfUfUfGA CAAGUCUUA GAGAUGAUC AUfCfUfCfAAGUf GAUfGAUfCfCfdTsd C C CfUfUfACfdTsdT T 171 UGACCACAG 172 UUUAAUCCG 173 (NH2C6)UfgAfcCf 174 pusUfuAfaUfcCfgAfc UCGGAUUAA ACUGUGGUC aCfaGfuCfgGfaUfu UfgUfgGfuCfa(invdT) A A AfaAf(invdT) 171 UGACCACAG 172 UUUAAUCCG 175 (NH2C6)uGAccAc 176 puUuAAUCCGACU UCGGAUUAA ACUGUGGUC AGucGGAuuAAA GUGGucAdTsdT A A dTsdT 171 UGACCACAG 172 UUUAAUCCG 175 (NH2C6)uGAccAc 177 UUuAAUCCGACUG UCGGAUUAA ACUGUGGUC AGucGGAuuAAA UGGUcAdTsdT A A dTsdT 247 GUUGGUGAA 248 CUGAGCUCC 251 (NH2C6)GfuUfgGf 252 pCfsUfgAfgCfuCfcAf UGGAGCUCA AUUCACCAA uGfaAfuGfgAfgCf uUfcAfcCfaAfc G C uCfaGf(invdT) (invdT) 247 GUUGGUGAA 248 CUGAGCUCC 251 (NH2C6)GfuUfgGf 255 pCfsUfgAfgCfuCfcAf UGGAGCUCA AUUCACCAA uGfaAfuGfgAfgCf uUfcAfcCfaAfcdTsdT G C uCfaGf(invdT) 249 GGUCCUGUU 250 AUUCACCAA 253 (NH2C6)GfgUfcCf 254 pAfsUfuCfaCfcAfaCf GUUGGUGAA CAACAGGAC uGfuUfgUfuGfgUf aAfcAfgGfaCfcdTsdT U C gAfaUf(invdT) 

What is claimed is:
 1. A compound of formula (I):

wherein: Y is a linker group selected from —(CH₂)₃— or —C(O)—N—(CH₂—CH₂—O)_(p)—CH₂—CH₂—; R¹ is —(C1-6) alkyl; —(CH₂)-naphthyl; or —(CH₂)_(m)-phenyl, which phenyl is unsubstituted or up to four times substituted with a substituent independently selected from: —NO₂, —CN, Halogen, —O—(CH₂)-phenyl, —O—(C1-6) alkyl, or —C(O)—NH₂; R² is hydrogen; —(CH₂)_(k)—N—C(Ph)₃, which phenyl rings are unsubstituted or independently substituted with —O—(C1-4)alkyl; —(CH₂)_(k)—C(O)—NH₂; —(CH₂)_(k)-phenyl; —(C1-6) alkyl, which is unsubstituted or once substituted with —S—CH₃; R³ is —NH-phenyl, which phenyl group is further substituted with a substituent independently selected from: —(CH₂)—OH; or —(CH₂)—O—C(O)—O-(4-nitro-phenyl); k is 1, 2, 3, 4, 5, 6; m is 1, 2, 3 or 4; n is 0 or 1; and p is an integer from 1 to
 20. 2. The compound of claim 1, having the conformation as shown in formula (Ia):


3. The compound of claim 1, wherein Y is —(CH₂)₃—.
 4. The compound of claim 3, wherein: Y is —(CH₂)₃—; R² is —(CH₂)_(k)—N—C(Ph)₃, which phenyl rings are unsubstituted or independently substituted with —O—(C1-4)alkyl; and R³ is —NH-phenyl, which phenyl group is further substituted with —(CH₂)—O—C(O)—O-(4-nitro-phenyl); n is 0; and R¹ and k are as defined in claim
 1. 5. The compound of claim 1, wherein Y is —C(O)—N—(CH₂—CH₂—O)_(p)—CH₂—CH₂—.
 6. The compound of claim 5, wherein: Y is —C(O)—N—(CH₂—CH₂—O)_(p)—CH₂—CH₂—; R² is —(CH₂)_(k)—N—C(Ph)₃, which phenyl rings are unsubstituted or independently substituted with —O—(C1-4)alkyl; and R³ is —NH-phenyl, which phenyl group is further substituted with —(CH₂)—O—C(O)—O-(4-nitro-phenyl); n is 0; and R¹, k and p are as defined in claim
 1. 7. A method of using the compound of claim 1 as a ligand of a biologically active compound, wherein said ligand is covalently attached to the biologically active compound.
 8. The method of claim 7, wherein said biologically active compound is a peptide.
 9. The method of claim 7, wherein said biologically active compound is a nucleic acid.
 10. The compound of claim 1, wherein it is have the following formula (II):

wherein: R^(a) is —(CH₂)_(k)—NH₂; R¹ and k are as defined in claim 1 for formula (I); and the biologically active substance is a nucleic acid, a protein or a peptide.
 11. The compound of claim 10, having the conformation as shown in formula (IIa):

wherein: R^(a) is —(CH₂)_(k)—NH₂; R¹ and k are as defined in claim 1 for formula (I); and the biologically active substance is a nucleic acid, a protein or a peptide.
 12. The compound of claim 10, wherein the biologically active compound is a protein or a peptide.
 13. The compound of claim 10, wherein the biologically active compound is a nucleic acid.
 14. The compound of claim 13, wherein the nucleic acid is an oligonucleotide comprising: an antisense strand with the modification pattern 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-3′, wherein w is independently a 5′-phosphate or 5′-phosphothioate or H, Z1 is independently a 2′-modified nuleoside. Z2 is independently a 2′-deoxy nucleoside or 2′-Fluoro-modified nucleoside, Z3 is independently a 2′-modified nucleoside, n_(a) is 8-23 and n_(s) is 8-25.
 15. The compound of claim 13, wherein the nucleic acid is a siRNA.
 16. The compound of claim 13, wherein the nucleic acid is covalently attached to a delivery polymer.
 17. A pharmaceutical composition comprising the compounds of claim
 10. 18. A method of using the compound of claim 10 comprising the step of delivering in vivo a biologically active compound.
 19. A method of using the compound of claim 10 for in vivo delivery of the biologically active compound, comprising the step of coadministering a conjugate with a delivery polymer.
 20. An oligonucleotide comprising: an antisense strand with the modification pattern 5′-(w)-(Z1)-(Z2)-(Z3)n_(a)-3′ and a sense strand with the modification pattern 5′-(Z3)n_(s)-3′, wherein w is independently a 5′-phosphate or 5′-phosphothioate or H, Z1 is independently a 2′-modified nuleoside. Z2 is independently a 2′-deoxy nucleoside or 2′-Fluoro-modified nucleoside, Z3 is independently a 2′-modified nucleoside, n_(a) is 8-23 and n_(s) is 8-25.
 21. The oligonucleotide of claim 20, wherein Z1 is a 2′-Fluoro-modified nucleoside or a 2deoxy-nucleoside and all remaining substituents as well as the variables n_(a) and n_(s) are as defined in claim
 1. 22. The oligonucleotide of claim 20, wherein Z3 is a 2′-O-Methyl modified nucleoside, a 2′-Fluoro-modified nucleoside or a 2deoxy-nucleoside and all remaining substituents as well as the variables n_(a) and n_(s) are as defined in claim
 1. 23. The oligonucleotide of claim 20 covalently linked to a delivery polymer.
 24. A conjugate comprising an oligonucleotide of claim 20 and cholesterol.
 25. A conjugate comprising an oligonucleotide claim 20 and a compound of the formula (IV):


26. A conjugate of a small molecule and an oligonucleotide of claim 20, wherein the small molecule comprises a nucleotide linker comprising 1-10 2′OH-nucleotides; and the oligonucleotide is covalently attached to the nucleotide linker of the small molecule.
 27. The conjugate according to claim 26, wherein the small molecule is cholesterol or a compound of the formula (V):

wherein R is a nucleotide linker comprising 1-10 2′OH-nucleotides.
 28. A pharmaceutical composition comprising an oligonucleotide according to claim 20 or a conjugate according to claim
 24. 